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Résumé  
L'athérosclérose est une maladie inflammatoire chronique caractérisée par 
l'accumulation de cholestérol dans la paroi artérielle et associée à une réponse immunitaire 
anormale dans laquelle les macrophages jouent un rôle important. Récemment, il a été 
démontré que les vaisseaux lymphatiques jouent un rôle primordial dans le transport inverse 
du cholestérol (Martel et al. JCI 2013). L’objectif global de mon stage de maîtrise a été de 
mieux caractériser la dysfonction lymphatique associée à l’athérosclérose, en étudiant de plus 
près l’origine physiologique et temporelle de ce mauvais fonctionnement. Notre approche a 
été d’étudier, depuis l’initiation de l’athérosclérose jusqu’à la progression d’une lésion 
athérosclérotique tardive, la physiologie des deux constituants principaux qui forment les 
vaisseaux lymphatiques : les capillaires et collecteurs lymphatiques. En utilisant comme 
modèle principal des souris Ldlr-/-; hApoB100+/+, nous avons pu démontrer que la dysfonction 
lymphatique est présente avant même l’apparition de l’athérosclérose, et que cette dysfonction 
est principalement associée avec un défaut au niveau des vaisseaux collecteurs, limitant ainsi 
le transport de la lymphe des tissus périphériques vers le sang. De plus, nous avons démontré 
pour la première fois l’expression du récepteur au LDL par les cellules endothéliales 
lymphatiques. Nos travaux subséquents démontrent que ce défaut de propulsion de la lymphe 
pourrait être attribuable à l’absence du récepteur au LDL, et que la dysfonction lymphatique 
observée précocement dans l’athérosclérose peut être limitée par des injections systémiques de 
VEGF (vascular endothelial growth factor) –C. Ces résultats suggèrent que la caractérisation 
fonctionnelle de la capacité de pompage des vaisseaux collecteurs serait une condition 
préalable à la compréhension de l'interaction entre la fonction du système lymphatique et la 
progression de l'athérosclérose. Ultimement, nos travaux nous ont amené à considérer de 
nouvelles cibles thérapeutiques potentielles dans la prévention et le traitement de 
l’athérosclérose. 
 
Mots-clés : athérosclérose, vaisseaux lymphatiques, cellules endothéliales lymphatiques, 
cellules musculaires lisses lymphatiques, lipoprotéines, transport cellulaire, inflammation. 
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Abstract  
Atherosclerosis is driven by the accumulation of cholesterol in the arterial wall, which 
triggers an inappropriate immune response in which macrophages play an important role. It 
has now been shown that the lymphatic vessels play an important role in reverse cholesterol 
transport (Martel et al. JCI 2013). The overall objective of my Master internship was to better 
characterize lymphatic dysfunction associated with atherosclerosis, studying closely the 
physiological and temporal origin of this pathological feature. Our approach was to study, 
from the initiation of atherosclerosis to the progression of the atherosclerotic lesion, the 
physiology of the two main components that form the lymphatic vessels: the lymphatic 
capillaries and collectors. Using a mouse model that closely resembles human atherosclerosis 
(Ldlr-/-; hApoB100+/+) we have demonstrated that lymphatic dysfunction is present before the 
onset of atherosclerosis, and that this dysfunction is primarily associated with a defect in the 
collecting vessels, thereby limiting the lymph transport from peripheral tissues to the blood. In 
addition, we have clearly demonstrated, for the first time to our knowledge, the presence of the 
LDL receptor on lymphatic endothelial cells. Our subsequent work shows that this reduction 
in lymph flow could be due to the absence of the LDL receptor, and that lymphatic transport 
can be restored by systemic injections of VEGF (vascular endothelial growth factor) –C. 
These results suggest that the functional characterization of the pumping capacity of the 
collecting vessels would be a prerequisite for the understanding of the interactions between the 
function of the lymphatic system and the progression of atherosclerosis. Altogether, our work 
unveils new potential therapeutic targets for the prevention and treatment of atherosclerosis. 
 
Keywords: atherosclerosis, lymphatic vessels, lymphatic endothelial cells, lymphatic smooth 
muscle cells, lipoproteins, cellular transport, inflammation. 
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1. INTRODUCTION 
Cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs 
are characterized by disorders of the heart and blood vessels, and so, most deaths are from 
heart attacks caused by sudden blood clots in the heart’s arteries1. Atherosclerosis is the 
principal cause of coronary artery disease (CAD), affecting large- and medium-sized arteries. 
Although atherosclerosis is a chronic inflammatory disease that remains asymptomatic for 
many years, its development is progressive and cumulative2.  An advanced plaque can rupture 
depending on its vulnerability, often leading to the formation of a circulating thrombus that 
will slow down, or completely stops blood flow through heart arteries causing death of the 
surrounding tissues3. All these events can produce devastating results, such as stroke, or even 
worse, death.  
Macrophages and cholesterol are the two main constituents driving the inflammatory 
response that characterizes atherosclerosis. Lipoproteins such as low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL) play an important role in atherosclerotic lesion 
modulation. LDL particles get trapped in the artery wall of the vessel where they are more 
prone to free radical oxidation than while circulating in the bloodstream4. Oxidized LDL 
(OxLDL) further aggravate plaque formation through recruitment of pro-inflammatory 
factors5. On the other hand, HDL is a key element in atherosclerosis modulation because of its 
role in reverse cholesterol transport, a process that helps with cholesterol removal from 
plaque, and its delivery to the liver and/or the intestines for eventual excretion6. Therefore, to 
halt atherosclerosis progression, emphasis has been put on increasing the levels of HDL 
directly, or by inhibiting cholesterylester transfer protein (CETP), which normally transfers 
cholesterol from HDL to very low-density lipoprotein (VLDL) or LDL6. Unfortunately, the 
clinical outcomes revealed disappointing negative results7-9, which made the scientific 
community re-think the way they approach the development of therapies that aim to promote 
the movement of cholesterol out of the artery wall. The identification and validation of the 
pathogenic mechanisms underlying this disease became a prerequisite. 
New findings offer novel insight into the path that cholesterol trapped in peripheral 
tissues follows during cholesterol mobilization for eventual excretion outside of the body. The 
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lymphatic system was identified as a novel prerequisite player in the removal of cholesterol 
from the atherosclerotic lesion (Martel et al. JCI 2013)10. It has been shown that without a 
functional lymphatic network, cholesterol gets trapped in the artery wall and potentially 
aggravates the disease. It is suggested that the lymphatic system cleans up arteries by 
promoting cholesterol transport out of atherosclerotic lesions10. The lymphatic vessels are 
composed of two main components, namely the absorptive lymphatic capillaries, responsible 
for the uptake of cells, molecules and fluid, and the collecting vessels, characterized by 
pumping units (lymphangions) that are propelling the lymphatic content toward the blood 
circulation in a unidirectional manner11. The relative roles of the lymphatic capillaries and 
collectors in the onset of the atherosclerotic disease are still unclear. 
 This present work will help better delineate the specific functional roles of the 
lymphatic system throughout the atherosclerotic process.  
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1.1 Atherosclerosis 
1.1.1 Pathogenesis of atherosclerosis: a multifactorial process 
Atherosclerosis is the principal cause of mortality worldwide and is at the origin of 
most cardiovascular diseases12. It is a chronic inflammatory disease that affects large- and 
medium-sized arteries, and is now considered a multifactorial disease that involves the 
interplay between genetic, intrinsic and environmental factors. Atherosclerosis occurs when 
the arteries become clogged with fatty deposits, also called plaque, and they lose their 
elasticity while decreasing the lumen space, leading to reduced blood flow, or even worse, a 
total blockade of the vessel. 
The artery wall is comprised of three different layers, which from the inside outwards, 
are: the intima, the media and the adventitia (Fig. 1). The intima is the thinnest and innermost 
layer, and it is at this level that atherosclerosis develops. It is composed of a single layer of 
endothelial cells displaying various properties including metabolic activities, 
thromboresistance, immune functions and elasticity13. The media is the thickest of the three 
layers. It is the main constituent of the artery and consists of smooth muscle cells (SMCs) 
surrounded by an extracellular matrix composed of elastic and fibrous proteins (collagen and 
elastin). In general, the media is avascular, except its outer regions, which are perfused by the 
vasa vasorum of the adventitia (tunica externa)13. The latter is the external layer of the blood 
vessel wall that consists of loosely organized connective tissue rich in collagen and elastic 
fibers, as well as fibroblasts and adipocytes. The adventitia ensures the anchorage of the 
arteries to the surrounding structures and is sometimes also traversed by longitudinal smooth 
muscle fibers13.  
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Figure 1. Structure of the artery wall.  
Illustration showing the different layers of a blood vessel wall. Adapted from Servier Medical 
Art http://www.servier.com/slidekit/?item=16 
 
Atherosclerotic plaque formation is a continuous process and can extend around the 
entire circumference of the vessel. Plaque development is slow, gradual and remains 
asymptomatic for a long time5. Monocyte-derived macrophages and resident macrophages 
accumulate in the aortic intima14; they engulf lipids and become foam cells, and produce a 
wide-ranging spectrum of inflammatory mediators15-17. The physiological mechanism through 
which cholesterol homeostasis is obtained in the artery wall, characterized by its mobilization 
from foam cells and subsequent transfer from the peripheral tissues to the liver and the 
intestines for further excretion, is called macrophage reverse cholesterol transport (mRCT)18. 
The removal of cholesterol from foam cells and plaques is essential for the reduction of 
atherosclerosis burden and plaque rupture19.  
1.1.2 Lipid metabolism and its role in atherosclerosis  
Triglycerides, cholesterol and different lipoproteins are well known to be involved in 
the pathogenesis of atherosclerosis20. A high ratio of HDL: LDL in the body is associated with 
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a lower risk of CAD21, and both entities play a pivotal, yet opposite role, in the modulation of 
atherosclerosis. 
LDL is directly involved in the development of atherosclerosis, mostly due to its 
accumulation in the endothelium of the blood vessel. The required receptor for the endocytosis 
of cholesterol-rich LDL is found mainly at the surface of hepatocytes and is called the LDL 
receptor (LDLR). If not enough of these receptors are present, cholesterol uptake by the cells 
is reduced, leading to increased cholesterol in the blood vessels22. A commonly known genetic 
disorder, familial hypercholesterolemia, is characterized by the inability of LDL particles to be 
removed from the body and therefore leads to a severe increase in the risk of cardiovascular 
disease23. LDL is composed of apolipoproteins, phospholipids, triglycerides and cholesterol. 
Its most important and atherogenic component is apolipoprotein B (ApoB), more precisely 
apoB100, which is synthetized by the liver. It is this outer phospholipid layer of the LDL 
particles that binds to LDLR24. ApoB100 is also present in other lipoproteins such as VLDL, 
intermediate-density lipoproteins (IDL) and chylomicrons. However, the main protein of IDL 
and chylomicrons is apolipoprotein E (ApoE), which is primarily produced by the liver and 
macrophages, and also mediates cholesterol metabolism25. The initial retention of LDL in the 
vessel wall, followed by its oxidation, is the primary event in the early stages of an 
atherosclerotic lesion development, and this oxLDL promotes further recruitment and 
retention of monocytes that become macrophages. The protein portion of LDL will then be 
modified, which will lead to its impaired recognition by the LDLR and instead, increase its 
recognition by scavenger receptors and oxLDL receptor that are not regulated by cholesterol 
content in the cell26,27. Overall, this leads to overaccumulation of cholesterol, and both of these 
derivatives will go on to activate endothelial cells, SMCs and macrophages, which in the end 
will facilitate vasoconstriction, thrombosis and platelet aggregation. Furthermore, the uptake 
of oxLDL by these monocyte-derived macrophages will lead to the formation of foam cells in 
the subendothelial space, and in the end, all these support the formation of the atherosclerotic 
lesion28.  
Interestingly, LDLR is tightly regulated by a proprotein convertase subtilisin/kexin 
type-9 (PCSK9), which binds to it and targets it for lysosomal degradation in cells, leading to 
decreased hepatic clearance of plasma LDL-cholesterol (LDL-C). In addition to modulating 
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cholesterol transport and metabolism, PCSK9 also promotes intestinal overproduction of 
triglyceride-rich apoB lipoproteins29. However, since PCSK9 interferes with the clearance of 
LDL-C from the blood, its loss-of-function mutations are associated with up to 85% lower 
plasma LDL-C levels30 and offer significant protection from coronary heart disease, such as 
atherosclerosis31. PCSK9 is now considered a great target for cholesterol-lowering therapies32. 
In the largest monotherapy trial using a PCSK9 inhibitor to date, Evolocumab reduced LDL-C 
from baseline by 55% to 57% more than placebo and 38% to 40% more than ezetimibe, which 
lowers cholesterol absorption from the intestine and was well tolerated in patients with 
hypercholesterolemia33. Furthermore, as statin intolerance has been a major limitation in the 
use of statins, a first and only study of a new class of LDL-C-lowering agents in patients 
selected with a rigorously documented intolerance to statins showed promising results. 
Alirocumab reduces LDL-C levels by approximately 50% when used as monotherapy, and has 
so far shown a safety profile comparable with ezetimibe or placebo34. On July 24, 2015 the 
first PCSK9 inhibitor, Alirocumab was approved by the FDA as a second line of treatment for 
adults with high cholesterol not controlled by diet and statin treatment. On August 2015, the 
FDA approved a second PCSK9 inhibitor, Evolocumab, for patients who are unable to get 
their LDL cholesterol under control with current treatment options. Moreover, PCSK9 has also 
been shown to affect the regulation of epithelial Na+ channel (ENaC) trafficking and therefore 
modulate epithelial Na+ absorption that is critical for blood pressure control35. Therefore, 
PCSK9 inhibition could be effective by its direct modulation of LDL-C uptake by the liver, 
but it could also potentially be associated with pleiotropic effects. So far, PCSK9 inhibition 
has an excellent safety profile and promises to provide a well-tolerated and effective 
therapeutic measure against coronary heart disease (CHD)36. 
Another key element in atherosclerosis is HDL, which is the smallest of the lipoprotein 
particles, but it is the densest because it contains the highest proportion of proteins to lipids. Its 
most abundant apolipoprotein is apolipoprotein A-1 (ApoA-1)37. Most protective effects of 
HDL are mediated by its cell surface receptors. HDL counteracts the proatherogenic activity 
of LDL by mobilizing cholesterol from the arterial intima and delivering it to the scavenger 
receptor class B1 (SR-B1), present on the surface of the liver, for further elimination into the 
bile38. In humans, one of the most relevant pathways is the indirect one, which is mediated by 
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CETP, a protein that exchanges triglycerides of VLDL for cholesteryl esters of HDL and leads 
to the processing of VLDLs to LDL, which will then be removed from circulation by the 
LDLR pathway39. Furthermore, it has been shown that HDL can function as an acceptor, 
transporter and inactivator of oxLDL, and is also responsible for the inhibition of monocyte 
adhesion in the intima of the blood vessel, preserves endothelium-dependent vascular activity 
through its effect on endothelial nitric oxide synthase (eNOS) and prevents thrombosis40.  
Therefore, HDL particles are important because unlike the larger particles, such as LDL, they 
transfer cholesterol away from cells, artery walls and tissues, through the bloodstream, back to 
both LDL particles, as well as back to the liver for excretion.  
The inverse relationship between HDL-cholesterol levels and CHD incited a lot of 
interest in pharmacological agents that elevate plasma levels of HDL. Statins are first-line 
drugs for the treatment of dyslipidemias and CAD prevention due to their ability to lower 
plasma LDL-C levels41. This treatment focuses mainly on endogenous LDL-C, and results in 
neglect of other important aspects of lipoprotein metabolism42. Significant side effects such as 
severe muscular pain are also displayed in most patients43. As statins offer little to no effect on 
increasing HDL levels, the attempt was then focused on other ways to increase these levels, 
such as directly through the inhibition of CETP, which normally transfers cholesterol from 
HDL, to VLDL or LDL44. Examples include HDL-raising drugs such as torcetrapib, which 
ended up showing an increase in cardiovascular risk45, as well as dalcetrapib, that simply 
lacked effectiveness46. Niacin, or Vitamin B3, are other effective HDL-raising agents currently 
on the market that first emerged as dyslipidemia treatment47. As a result, new ways to 
approach treatments, particularly those aimed at preventing plaque development in 
atherosclerosis, are currently under close investigation, and as we will soon see in the sections 
to come, there are promising venues ahead.  
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1.2 The lymphatic system 
1.2.1 General anatomy and functions of the lymphatic system 
The lymphatic system is part of the circulatory system and plays a vital role in host 
defense and adaptive immunity. Although the roles of lymphatic vessels in tissue maintenance 
and disease are now well known, their origins are still a subject of debate. As far back as 1902, 
Florence Sabin, based upon results obtained by India ink injection experiments in pigs, 
proposed that isolated primitive lymph sacs, which are precursors of the lymph vessels, 
originated from endothelial cells that bud from the cardinal vein during early development48. 
Interestingly, Klotz et al. found that the lymphatic endothelial cells (LECs) that form 
lymphatic vessels in the heart originate both from embryonic veins and from other non-venous 
sources, like the yolk sac49. Therefore, contrary to previous belief, it has been proven that a 
significant part of the dermal lymphatic vasculature forms independently of sprouting from 
veins50. Many different transcription factors regulate lymphatic development, one of the most 
crucial being Prospero-related homeobox-1 (Prox1)51. Cells that are Prox1+ depend on a 
paracrine factor called VEGF-C to be able to spread away from the embryonic veins. The 
vascular endothelial growth factor receptor-3 (VEGFR-3) serves as a receptor for lymphatic-
specific VEGFs, VEGF-C and VEGF-D. VEGF-C is important for normal development of the 
lymphatic vessels and Prox1 drives VEGFR-3 expression that enables LECs to respond to 
VEGFR-3 ligands52. In zebra fish, it has been shown that VEGF-D can compensate for the 
absence of VEGF-C, making the latter dispensible53. Separation of lymphatic fluid from blood 
requires platelet aggregation54. Platelets regulate the blood/lymphatic vessel separation by 
inhibiting the proliferation, migration, and tube formation of LECs, upon activation by C-type 
lectin-like receptor 2 (CLEC-2)/podoplanin interaction. Interaction of podoplanin present on 
LECs with CLEC-2 present on platelets triggers a signalling cascade leading to platelet 
aggregation and the formation of fibrin-containing platelet thrombi that protect both the 
lymphovenous junction (LV) and the thoracic duct from backward flow55. 
Characterized by a network of vessels that carry a clear fluid called lymph, the 
lymphatic system is now recognized as working in close collaboration with the cardiovascular 
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system, but unlike the circulatory system, it is not a closed system56. One of its main roles is to 
maintain fluid homeostasis in the body with the help of its thin-walled and blind-ended 
lymphatic capillaries57. These initial lymphatics help absorb the ultrafiltrates from peripheral 
tissues, they are highly permeable and are constituted of specialized, discontinuous ‘button-
like’ junctions between endothelial cells58. Lymphatic capillaries are characterized by the 
absence of SMCs and at the surface of the LECs they specifically express lymphatic vessel 
endothelial hyaluronan receptor (LYVE-1). Following its absorption by the lymphatic 
capillaries, lymph will move on to converge into larger pre-collecting vessels, to subsequently 
reach the collecting lymphatic vessels57,59. Lymphatic capillaries have a sparse and 
discontinuous basement membrane and they lack pericytes, which are the contractile cells that 
wrap around the endothelial cells of blood capillaries and venules throughout the body. 
Anchoring filaments attach LECs to the extracellular matrix and prevent vessel collapse under 
conditions of increased interstitial pressure. Both “buttons” and “zippers” are composed of 
adherens and tight junction–associated proteins like VE-cadherin, zonula occludens-1, 
occludin, and claudin-5 (Fig. 2). The main difference between them resides in their 
organization60. Collecting lymphatic vessels are covered with continuous basement membrane 
and SMCs, and are characterized by the expression of podoplanin. Therefore, collecting 
vessels are contractile lymphatics that propel lymph in a unidirectional manner, with the help 
of intraluminal bi-leaflet valves, as well as smooth muscle walls. The functional unit of a 
collecting lymphatic vessel is called a lymphangion, representing the segment between two 
valves. All the lymph collected from the entire left side of the body, the digestive tract and the 
right side of the lower part of the body flows into a single major vessel, the thoracic duct. The 
latter empties into the left subclavian vein. The lymph in the right side of the head, neck, and 
chest is collected by the right lymph duct and empties into the right subclavian vein. The two 
subclavian veins will then drain into the blood circulation through the LV, right near their 
junction with the internal jugular veins59.  
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Figure 2. Organization of the lymphatic vasculature.  
(A) The lymphatic vasculature is responsible for the absorption of fluid, macromolecules, and 
cells from the interstitium. (B) Mechanism of lymph formation in capillaries. Interstitial 
components penetrate lymphatic capillaries via openings between LECs. The specialized 
structure of such openings prevents the return of lymph back to the interstitium. Anchoring 
filaments attach LECs to the ECM and prevent vessel collapse under conditions of increased 
interstitial pressure (black arrow). (C) Junctional organization of LECs in lymphatic capillaries 
and collecting vessels. Both “buttons” and “zippers” share a repertoire of adherens and tight 
junction–associated proteins, like VE-cadherin, zonula occludens, occludin, and claudin-5. 
The main difference between them resides in their organization58. (D) Mechanism of lymph 
propulsion in collecting vessels. Coordinated opening and closure of lymphatic valves is 
important for efficient lymph transport. SMCs covering each lymphangion possess intrinsic 
contractile activity. Schulte-Merker S, et al. Lymphatic vascular morphogenesis in 
development, physiology, and disease. J Cell Biol 2011; 193(4): 607-18. 
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1.2.2 The physiology of contraction  
Largely aqueous with relatively low concentrations of proteins and cells compared to 
blood, lymph is propelled through the collecting lymphatics via two primary mechanisms: 1) 
intrinsic, characterized by active pumping as a result of lymphatic muscle cell contraction, the 
lymphangions and the valves; 2) extrinsic, compression mechanisms such as the movement of 
skeletal muscle or other tissues surrounding the lymphatics, as well as respiration. Coordinated 
opening and closure of lymphatic valves is important for efficient lymph transport. As 
previously discussed, lymphangions are wrapped in a disorderly manner by lymphatic smooth 
muscle cells61. Unlike vascular smooth muscle, lymphatic muscle is characterized by both a 
rapid, phasic contractile activity that drives the intrinsic lymphatic pumping, as well as a 
slower, tonic form of contractions seen in blood SMCs. The uniqueness of lymphatic 
contractility is due to the lymphatic muscle being composed of both smooth and striated 
muscle62. However, lymphatic valve function, which operates in an open–close manner, is 
passive and responds to the pressure difference between pre- and post-valve lymphagions63. In 
contrast, lymphangion contraction is an active process that requires the generation of force by 
SMCs, which are mainly dependant on myocyte intracellular Ca2+ levels. In this regard, a 
subset of muscle cells acts as pacemaker cells, initiating and driving propagation of the Ca2+
 
wave to other cells downstream, inducing a series of action potential-like spikes of calcium 
that cause the synchronized contractions of lymphangions64. Contraction by the lymphangions 
is an alternate process, and at the same time, it is normal for two or more adjacent 
lymphangions to contract and relax at the same time (Fig. 3)65.  
 
 
 12 
 
Figure 3. Examples of lymphangion coordination.  
(A) Contractions might alternate in adjacent lymphangions. (B) It is possible that two or more 
adjacent lymphangions contract and relax together. Adapted from: Munn LL. Mechanobiology 
of lymphatic contractions. Semin Cell Dev Biol 2015; 38: 67-74. 
 
Several mechanisms trigger and modulate vessel phasic or tonic contraction by 
influencing lympatic SMCs cytoplasmic Ca2+ levels. Modulation of the 20-kDa myosin light 
chain (MLC20) is an important factor of lymphatic contractile strength. MLC20 
phosphorylation is regulated by the activities of myosin light-chain kinase (MLCK) and 
myosin light-chain kinase phosphatase (MLCP). Lymphatic muscle contraction is initiated by 
an increase in cytosolic Ca2+ levels resulting in Ca2+ binding to the universal intracellular Ca2+ 
receptor protein, calmodulin (CaM), which will activate the catalytic subunit of MLCK. 
MLCK then phosphorylates MLC20, leading to lymphatic vessel contraction. MLC20 
phosphorylation is reversed by MLCP, resulting in lymphatic muscle relaxation66. The best-
known and most studied mechanism for interfering with SMC contraction is nitric oxide (NO), 
which acts at multiple points of the Ca2+ contraction pathway. NO produced by eNOS 
regulates systemic blood pressure, vascular remodelling and angiogenesis67. Shear stress is the 
most important physiological stimulus of its production and phosphorylation of eNOS by Akt 
represents a Ca2+-independent regulatory mechanism for activation of eNOS. When it comes 
to the lymphatic system, once produced, NO can diffuse to the SMCs enveloping the 
lymphatic vessels and affect pumping. It works by modulating Ca2+ release and uptake68, as 
well as the enzymes responsible for force production69,70. NO decreases vascular tone through 
a cGMP-dependent mechanism, which leads to reduced intracellular Ca2+, by inhibiting its 
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release from internal stores. Conversely, NO can activate several other channels to increase 
Ca2+ efflux71. NO also induces relaxation through its direct inhibitory effect on the MLC72.  
Overall, NO is a vasodilator that opposes the Ca2+ response of the lymphatic vessels, leading 
to dilatation and decreased contraction frequency73. Hence, the lymphatic system is under the 
constant influence of various factors that modulate its contractility, controlling its crucial roles 
both as conduit and pump.  
1.2.3 Lymph composition in lymphatic function 
Lymph composition is changed during its flow from the periphery, with its protein 
concentration increasing along the lymphatic vessels74. Since lymph is derived from the 
interstitial fluid, its composition constantly changes depending on its interaction between the 
surrounding cells and blood. Blood and the interstitial fluid are in dynamic equilibrium with 
each other, meaning that water and solutes can pass between the two by diffusion across gaps 
in capillary walls called intercellular clefts. Although peripheral lymph lipoproteins have been 
characterized in animals, information about their composition is limited, and their 
ultrastructure is nearly unexplored. Studies analyzing human lymph have started to emerge, 
and they have confirmed that lymph composition is different than that of plasma or serum10. 
Back in 2000, Nanjee et al. demonstrated that the concentration of small pre-beta HDLs in 
human tissue fluids is determined only in part by their transfer across capillary endothelium 
from plasma. They showed that the local production of pre-beta HDL in the periphery, by 
remodelling of spheroidal HDLs in tissue fluids, is just as important29. Continuing down this 
path, in 2001, Nanjee et al. examined the composition, as well as the ultrastructures of 
different subclasses of normal human peripheral lymph lipoproteins. Total cholesterol 
concentration in lymph HDL was 30% greater in lymph than could be explained by the 
transendothelial transfer of HDL from plasma, which provided direct confirmation that HDL 
acquire cholesterol in the extravascular compartment30.  
Extracellular vesicles (EVs) are plasma membrane-derived vesicles released from cells 
upon activation or during apoptosis. Cellular EVs in body fluids constitute a heterogeneous 
population, differing in cellular origin, numbers, size, antigenic composition and functional 
properties75. Despite being considered simple cellular debris for the longest time, it is now 
well documented that EVs can interact with neighboring cells and are suspected to be key 
 14 
players in many physiopathological processes such as thrombosis, autoimmune diseases and 
inflammation76. Due to their diversity, EVs are considered important biomarkers and thus, 
their precise detection in several biological fluids, such as lymph, is important to better 
understand all their different functional activities77. As they are an important vector of 
information exchange between cells of different origins, in the course of their various 
interactions they cause structural and functional changes, especially at the level of the vascular 
wall, in the endothelium78. Although EVs are present in the peripheral blood of healthy 
individuals, marked elevations occur in many disease states76, as they have been shown to be a 
major component of atherosclerotic plaques, especially platelet-derived EVs75. Therefore, in a 
pathological setting, particularly atherosclerosis, it is important to understand why and how 
the presence of EVs is affected, by studying lymph composition. 
We now know that a broad array of cytokines, proteins, growth factors, lipoproteins 
and maybe even extracellular vesicles are contained within lymphatic fluid, which play an 
important role in metabolism, proliferation, as well as immunoregulation76. We have yet to see 
just how much effect they may have on the lymphatic vessels themselves.  
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1.3 Lymphatic vessels in inflammation and cardiovascular 
diseases 
1.3.1 Mouse models of lymphatic dysfunction 
Several models with impaired lymphatic function have started to emerge. Primary 
congenital lymphedema (Milroy disease) is a rare autosomal dominant condition caused by 
mutations in the vegfr-3 gene79. Primary human lymphedema is characterized by a chronic and 
disfiguring swelling of the extremities. A popular mouse model to study the physiological 
regulation of lymph flow and to assess the therapeutic potential of VEGF-C to stimulate 
lymphatic revascularization has been put forth by Alitalo et al80. Chy mice have an 
inactivating VEGFR-3 mutation in their germ line and swelling of the limbs because of 
incomplete development of lymphatic vessels within the dermis. Furthermore, promising 
therapeutic results were observed when they used virus-mediated VEGF-C gene therapy, as 
they were able to generate functional lymphatic vessels in lymphedema mice81. Another 
example is the Prox1+/- mouse, which accumulates fat as a consequence of lymphatic vascular 
leakage, and has been used as a new model for adult-onset obesity and lymphatic vascular 
disease. Functional inactivation of a single allele of the Prox1 gene led to adult-onset obesity 
due to abnormal lymph leakage from mispatterned and ruptured lymphatic vessels82. Another 
interesting mouse model includes the microsurgical ablation of the lymphatic vessels in the 
tail of the mouse, which results in lymph stagnation, lymph vessel dilation (with a marked 
increase in tail volume), accumulation of fibroblasts, fat, and skin cells, impaired clearance of 
immune cells from the tail, and profound accumulation of inflammatory cells83. It is a useful 
model that closely imitates some key features of acquired lymphedema in humans, and in 
combination with a diverse array of mouse genetics, it could lead the way to the better 
understanding of the molecular basis of lymphedema. All these different mouse models have 
not only helped us to improve our understanding of different lymphatic-related pathologic 
conditions and their relationship with inflammation, but also to re-evaluate the functional roles 
of the lymphatic vascular network. 
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1.3.2 Lymphatic function in atherosclerosis 
Despite the well-defined roles of the lymphatic system in preserving fluid balance 
throughout the body by returning plasma proteins from interstitial spaces back to the blood 
circulation, its function in heart disease has lately been getting much attention. Alterations in 
the intestinal lymphatic network are well-established features of human and experimental 
inflammatory bowel disease (IBD)84. As lymphatic vessels play an essential role in intestinal 
lipid uptake, impairment of lymphatic vessel function leads to enhanced adipose tissue 
accumulation in patients with lymphedema and in genetic mouse models of lymphatic 
dysfunction85. Interestingly, Blum et al. showed that adipose tissue expansion due to a high-fat 
diet leads to functional impairment of the lymphatic vasculature, mainly at the level of the 
collecting vessels. In the heart, evidence shows that blocking cardiac lymph flow may 
contribute to several forms of cardiac injury including cardiac lymphedema and poor heart 
performance in animal and human heart studies86. It was back in 1981 that Lemole observed 
intimal vessel thickness following lymphatic vessel blockage. He suggested that the 
accumulation of interstitial fluid in the artery wall could be due to a phenomenon called 
lymphostasis, which may contribute to the development of atherosclerosis due to factors 
present in the intimal edema87. Thirty years later, fundamental studies and clinical studies 
started to emerge in this regard. Studies analyzing the morphology of lymphatic vessels in the 
artery wall allowed for insights between their associations with atherosclerosis. In animal 
models, lymphatic vessels have been observed in the adventitia of the artery wall88. In fact, Xu 
et al. associated the presence of lymphatic vessels within the adventitia of the artery wall an 
important factor for the draining of local inflammatory cells and cytokines from peripheral 
tissues89. In a clinical setting, Drozdz et al. took interest in the presence of lymphatics in the 
adventitia of the internal carotid artery in humans and showed that the number of adventitial 
lymphatics increases with the severity of atherosclerosis measured as intimal thickness90. 
Furthermore, they showed that arteries with a dense network of lymphatic vessels seem to be 
naturally protected against atherosclerosis when compared to those without such a network91. 
Martel et al. introduced a new integrated model of mRCT in which they clearly showed that 
without a functional lymphatic network, cholesterol cannot be properly conducted out of the 
artery wall. They used a surgical model of aortic transplant from a hypercholesterolemic ApoE 
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deficient (ApoE-/-) donor to a hypercholesterolemic ApoE-/- receiver in which ApoE vector 
was injected to induce cholesterol efflux, and showed that the pattern of the newly regrown 
lymphatic vessels post-transplant is influenced by the blood flow through the transplant10. The 
lymphatic vessels thus formed appeared to be atheroprotective: in conditions where lymphatic 
vessels had fully grown post-transplant, the cholesterol contained in the transplanted artery 
was able to exit the atherosclerotic lesion. By contrast, partial inhibition of lymphatic regrowth 
using VEGFR-3 antibody was reflected by retention of cholesterol in the artery wall of the 
transplanted aortic segment10. Along the same path, Vuorio et al. published that lymphatic 
impairment worsened the atherosclerotic plaque formation in atherogenic Ldlr-/-/ApoB100/100 
mice crossed with transgenic mice bearing localized lymphatic insufficiency (sVEGFR-3 or 
Chy), and analyzed the effects of the absence of lymphatics on lipoprotein metabolism and 
atherosclerosis92. The group observed a positive correlation between atheroma formation and 
the absence of lymphatic vessels, contrary to previous studies that showed opposite effects. 
This study further questions whether lymphatic vessels are beneficial or detrimental. 
Furthermore, these Ldlr-/-/ApoB100/100 mice crossed with transgenic mice bearing localized 
lymphatic insufficiency (sVEGFR-3 or Chy) have increased cholesterol levels leading to 
accelerated atherogenesis, which suggests that lymphatic vessels play a crucial role in the 
maintenance of proper lipoprotein metabolism and overall vascular homeostasis92.  
Based on the newly described integrated model for mRCT10, it is believed that within 
the atherosclerotic lesion, cholesterol ester (CE) is exported from macrophages and uploaded 
onto cholesterol acceptors like HDL, which will then cross the medial layer of the artery to 
reach the adventitia. From there, it will enter the adventitial lymphatic capillaries and get 
propelled through the afferent collecting lymphatic to the draining lymph node. It passes 
through the efferent collecting lymphatic to enter the bloodstream at the level of the 
subclavian vein10. The next steps are well studied and imply an uptake of the circulating 
cholesterol by the liver, via SR-B1 receptor93, where most cholesterol is transformed into bile 
acids and secreted into the bile for excretion. In parallel, CE from HDL can also be transferred 
in VLDL and LDL, via CETP94, a pathway that is not present in mice, and internalized by the 
liver via LDLR94,95, to also be secreted into the bile. Hence, it is crucial to redirect more 
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therapies towards improving lymphatic function, which should facilitate cholesterol clearance 
and limit inflammation, all in the hopes of preventing or reversing atherosclerosis.  
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2. RESULTS 
2.1 General mémoire objective  
The general objective of my M.Sc. project was to better delineate the functional roles 
of the lymphatic system before atherosclerosis onset and its progression. More specifically, I 
have studied the effect of in vivo modulation of the LDLR on lymphatic function. 
Based on published data by Dr. Martel10, we were able to pursue her work with newly 
formed hypotheses of our own. This new data I have helped acquire is now the stepping-stone 
to many upcoming projects currently being developed in our laboratory. Our first manuscript 
is presented in section 4.2. 
2.2 Presentation of the article 
In this article, we built on previously published results by Dr. Martel10, as well as the 
literature, to study the origin of the lymphatic dysfunction seen in atherosclerosis. The 
objective was to see at which level of the lymphatic vessel functional impairment originates 
and at what point during atherosclerosis development the defect becomes prominent.   
We characterized thoroughly in different mouse models the morphology and 
functionality of the lymphatic capillaries, and it gave us no reason to doubt that lymphatic 
dysfunction must surely originate at a higher level, namely the collecting vessels. Our next 
step was to better grasp the cellular composition of these vessels, and that is how we came to 
show that the LDLR is present even at the surface of LECs. As LDLR, whose expression is 
down-regulated by physiologic levels of PCSK9, is a major player in atherosclerosis, we 
aimed to investigate whether and how PCSK9 and LDLR modulation plays a role in lymphatic 
function.  
We subsequently observed that in a mouse model with an over-accumulation of LDLR, 
lymphatic function increased throughout age, when compared to wild type. In contrast, even 
before development of plaque, in an Ldlr-/-; hApoB100+/+ mouse model (also called ATX), an 
acute lymphatic dysfunction occurred. This new finding opened doors to the possibility of new 
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therapeutic targets such at VEGF-C, which we demonstrate may exert a rescue effect when 
treating young Ldlr-/-; hApoB100+/+ mice, before atherosclerosis onset.  
 
Overall, our results suggest that:  
x Lymphatic transport tends to improve with age in Pcsk9-/- mice compared to WT 
x LDLR is expressed on LECs and associated with lymphatic vessel function  
x Collecting lymphatic vessels may be responsible for the impairment in lymphatic 
function in Ldlr-/-; hApoB100+/+ mice 
x VEGF-C systemic treatment abrogates the lymphatic dysfunction that is observed 
before atherosclerosis onset in Ldlr-/-; hApoB100+/+ 
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ABSTRACT 
Atherosclerosis is driven by the accumulation of immune cells and cholesterol in the arterial 
wall. Although recent studies have shown that lymphatic vessels play an important role in 
macrophage reverse cholesterol transport, the mechanisms regulating this pathological feature 
remain unknown. In the current report, we aim to better characterize this lymphatic 
dysfunction associated with atherosclerosis by studying the physiological and temporal origins 
of this impairment. We observed that mice deficient in Pcsk9 had improved lymphatic 
function throughout age when compared to WT mice for up to six months, while displaying 
enhanced expression of LDLR on lymphatic endothelial cells. Then, using a mouse model 
(Ldlr-/-; hApoB100+/+) that closely resembles human atherosclerosis we show that lymphatic 
dysfunction is present before atherosclerosis lesion formation, and that this dysfunction is 
primarily associated with a defect in the lymphatic collecting vessels. Systemic treatment with 
a selective VEGFR-3 agonist (VEGF-C 152s) rescued this impairment in a cholesterol-
independent manner. Taken together, our results suggest for the first time that the absence of 
PCSK9 is associated with improved lymphatic function and unveil new potential therapeutic 
targets for the prevention and treatment of atherosclerosis. 
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Introduction  
 
Low-density lipoprotein receptors (LDLR) are important players in atherosclerotic lesion 
development and progression mostly through lipoprotein metabolism regulation1, as 
demonstrated in patients with familial hypercholesterolemia2. This genetic disorder is most 
often caused by reduced function of LDLR, apolipoprotein B (apoB) or gain-of-function 
mutations in protein convertase subtilisin kexin type 9 (PCSK9), resulting in a severe 
elevation of the plasma levels of LDL3. Circulating LDL-cholesterol (LDL-C) accumulates in 
the artery wall of blood vessels and leads to premature atherosclerosis4. ApoB100 is the 
apolipoprotein and ligand of LDLR found in lipoproteins synthesized by the liver, and is the 
sole protein of LDL5. LDLR is present on the outer surface of many types of cells6. 
Hepatocytes are important cells bearing LDLR, as the liver is responsible for removing most 
excess cholesterol from the body, through LDL uptake5. PCSK9 is a well-established down-
regulator of LDLR7, which acts by binding to the receptor causing its lysosomal degradation 
in cells. Since PCSK9 interferes with the clearance of LDL-C from the blood, its loss-of-
function mutations are associated with up to 85% lower plasma LDL-C levels8 and offer 
significant protection from coronary artery disease (CAD), like atherosclerosis9. On the 
contrary, high-density lipoprotein (HDL) reduces cardiovascular risk, mainly due to its role in 
macrophage reverse cholesterol transport (mRCT), promoting cholesterol removal from 
plaque and its eventual excretion by the liver and/or the intestines10,11. In order to halt 
atherosclerosis progression and decrease the prevalence of CAD, emphasis has logically been 
put on improving this physiological process. However, most of the different ways used to 
increase HDL levels did not demonstrate any clinical benefits, and did not lead to improved 
mRCT or decreased CAD12-14. Consequently, such conclusions made the scientific community 
re-think the way they approach the development of therapies aimed to increase mRCT and 
favourably modulate atherosclerosis.  
 
PCSK9 inhibition has an excellent safety profile in clinical trials and promises to provide 
a well-tolerated and effective therapeutic measure against CHD15. PCSK9 inhibition could act 
via its direct modulation of LDL-C uptake by the liver, but it could also potentially be 
associated with pleiotropic effects. Recent findings show that PCSK9 deficiency increases 
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CD36 levels in the liver and adipose tissue16 and reduces liver metastasis by its ability to lower 
cholesterol levels17. Moreover, PCSK9 has been shown to affect the regulation of epithelial 
Na+ channel (ENaC) trafficking and therefore modulate epithelial Na+ absorption, which is 
critical for blood pressure control18. Lastly, PCSK9 was shown to be expressed endogenously 
both at the mRNA and protein level in murine peritoneal macrophages19. Giunzioni et al. 
showed for the first time that this PCSK9 expression directly influences atherosclerotic plaque 
composition with no changes in serum cholesterol levels, which suggests a direct effect of 
macrophage PCSK9 in inflammation and plaque development20. 
 
An additional new therapeutic target in atherosclerosis has recently arisen. In a recent 
study, the lymphatic system has been identified as a novel prerequisite player in the removal 
of cholesterol from the atherosclerotic lesion by mRCT21. It has been reported that without a 
functional lymphatic network, cholesterol cannot leave the artery wall and might potentially 
aggravate the disease. Accordingly, it is now suggested that cholesterol leaves tissues and 
reaches the bloodstream by first entering lymphatic vessels (LVs), putting forward a new 
integrated model for mRCT21,22. The blood vasculature and the lymphatic systems are parallel 
and interdependent networks23. In contrast to the blood vascular network, the lymphatic 
vascular network is an open, unidirectional and low-pressure vascular system. Lymphatic 
development and regulation are dependent mostly upon VEGF-C/D and its receptor VEGFR-
324. The LVs are composed of two different entities, bearing distinct but complementary roles. 
Lymph is first absorbed through thin-walled and blind-ended initial lymphatics (also called 
lymphatic capillaries), which are highly permeable and are constituted of specialized, 
discontinuous "button-like" junctions between endothelial cells25. Expression of lymphatic 
vessel hyaluronan receptor 1 (LYVE-1) on the LEC and absence of smooth muscle cells 
(SMC), are characteristics of the lymphatic capillaries25. Following, lymph moves from the 
lymphatic capillaries into collecting vessels, the entities responsible of maintaining lymph 
flow through contraction of units called lymphangions. Collecting vessels resemble small 
veins, but have bi-leaflet valves between the contractile units in order to prevent back flow. 
They are also characterized by a basement membrane, down-regulation of LYVE-1 
expression, podoplanin expression, continuous "zipper-like" cell-cell junctions and a 
discontinuous SMC layer26. Lymph is propelled away from the periphery most of the time 
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against a hydrostatic pressure gradient primarily via the phasic and synchronized contractions 
of the lymphangions, mediated by the intrinsic contractility of SMC, the contraction of 
surrounding skeletal muscles, and arterial pulsations27-31. 
 
Since lymphatic function is now linked to atherosclerosis, and the LDLR plays a central 
role in cardiovascular disease and exhibits modulation following PCSK9 inhibition treatment, 
studying the implication of PCSK9 on lymphatic function has become of great interest. 
Herein, we sought to better characterize the interplay between lymphatic function and the 
onset and progression of atherosclerosis by exploring the possible link between lymphatic 
function and LDLR modulation in Pcsk9-/- and Ldlr-/-; hApoB100+/+ mice. We investigate 
whether and how the absence of PCSK9 and, subsequently, increased LDLR protein 
expression has a beneficial effect on lymphatic function, and further portrays the premises of 
the chronological sequence of atherosclerosis-associated lymphatic dysfunction.  
 
 
Results  
 
Lymphatic vessel function is enhanced in Pcsk9-/- mice.  
As PCSK9 targets and mechanisms of action are now known not to be solely confined to 
the liver, we sought to investigate its effect on lymphatic function. We herein hypothesized 
that knocking out Pcsk9 may positively modulate lymphatic transport. To address this, we first 
assessed the capacity of popliteal lymphatic vessels to carry Evans blue (EB) dye from the 
initial lymphatics located in the dermis of the foot pad up to the collecting lymphatics and the 
corresponding draining popliteal lymph node (LN) (Fig. 1a, upper panel; Supplementary Fig. 
S1 online). Intradermal injection of EB dye revealed that the dye intensity was greater within 
the dominant32 collecting vessel of Pcsk9-/- mice, with no or little interruption on its path (Fig. 
1b, lower panel, green arrow vs. red arrows). This observation suggests that lymphatic 
collecting vessel function was improved in Pcsk9-/- mice when compared to atherosclerosis-
prone Ldlr-/-; hApoB100+/+ and even WT mice. In addition, less extravasated EB dye was 
detected in the surrounding adipose tissue of Pcsk9-/- mice when compared to that of Ldlr-/-; 
hApoB100+/+ mice, signifying an improved lymphatic collector function. 
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As a complementary measure of lymphatic function, we evaluated the efficiency of 
lymphatic vessels to transport dendritic cells from the peripheral tissue to the corresponding 
draining LNs, using the well-described FITC painting assay33. Similar to the improved EB dye 
transport, the migration of skin dendritic cells (CD45+CD11c+FITC+) in Pcsk9-/- mice (Fig. 1b) 
was improved when compared to WT mice at 6 months. Analysis of the back skin from that 
same region (Supplementary Fig. S2a online) revealed that the adipose tissue layer tends to be 
thinner in 3-month-old Pcsk9-/- mice when compared to WT mice (Supplementary Fig. S2b 
online), but not in 6- (Supplementary Fig. S2c online) and 12- (Supplementary Fig. S2d 
online) month-old Pcsk9-/- mice. 
  
Initial lymphatic vessel morphology and number are unchanged in Pcsk9-/-. 
As hypercholesterolemia-associated lymphatic dysfunction in 16-week-old apoE−/− mice 
is associated with initial lymphatic hyperplasia34, we conversely sought to investigate whether 
the absence of PCSK9 would be associated with morphological changes within initial 
lymphatics. We first assessed initial lymphatic vessel (Lyve-1+) morphology and density (Fig. 
2a) by looking at their diameter (Fig. 2b), their number (Fig. 2c) and the total surface area 
occupied by the vessels (Fig. 2d) in the mouse ear dermis. No significant changes were 
observed in the athero-protected mouse model when compared to WT mice in an age-
dependent manner. In order to confirm our finding in the artery wall, we investigated the 
presence of initial lymphatic in the adventitia of the aortic sinus (Fig. 2e), a blood vessel layer 
where lymphatic vessels have been consistently observed35.Once again, no difference was 
seen at any age when looking at the morphology or density of Lyve-1+ vessels (Fig. 2f-h).  
 
LDLR is expressed on lymphatic endothelial cells of popliteal collecting vessel. 
Based on our findings that lymphatic function is improved in Pcsk9-/- mice without 
apparent modulation in initial lymphatic morphology or growth, we sought to investigate 
whether collecting LVs could thus be responsible for the observed related lymphatic gain-of-
function observed in this Pcsk9-/- mouse model. To begin with, we hypothesized that LDLR 
per se could act as an important modulator in lymphatic collecting vessel function, as it would 
be drastically increased on LVs compared to WT mice. Our initial step was to detect the 
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presence of LDLR on collecting LVs and then test its modulation by PCSK9. Therefore, for 
the first time to our knowledge, we have shown that LDLR was expressed on popliteal 
lymphatic collecting vessels (Fig. 3a). Immunofluorescence was performed and demonstrated 
the presence of LDLR on podoplanin+ LECs, but to a lesser extent smooth muscle cells (SMC, 
Fig. 3a). Immunofluorescence (Fig. 3b) and western blots performed with equal amount of 
protein loading (Fig. 3c) revealed that Pcsk9-/- mice displayed a LDLR overaccumulation 
phenotype when compared to WT and Ldlr-/- mice. 
 
Lymphatic dysfunction appeared before atherosclerosis onset and decreased during its 
progression in Ldlr-/-; hApoB100+/+ mice.  
As our data are bridging lymphatic function to LDLR modulation on lymphatic collecting 
vessel ECs through PCSK9, we next conversely investigated whether decreased LDLR levels 
per se could be a premise to lymphatic collecting vessel dysfunction. Atherosclerosis-prone 
Ldlr-/-; hApoB100+/+ mice are severely dyslipidemic, exhibit premature blood endothelial 
dysfunction, oxidative stress and inﬂammation at 3-month-old36-38.They spontaneously 
develop aortic atherosclerotic lesions after 4 months while on regular chow diet. Before that 
age, they do not have atherosclerotic lesions, but as they get older, they become increasingly 
atherosclerotic (Supplementary Fig. S3a, S3c, S3d online). Resembling the human 
atherosclerotic phenotype due in part by the addition of the human apoB100 transgene, these 
mice are a suitable model to study in further detail factors that could lead to atherosclerosis or 
at least impact its progression. Lymphatic transport assays revealed a significant (p<0.001) 
lymphatic function impairment in 3-month-old Ldlr-/-; hApoB100+/+ mice (Fig. 4a) that are not 
yet bearing atherosclerotic lesions (Supplementary Fig. S3a, S3c, S3d) or macrophages in the 
artery wall (Supplementary Fig. S3b and S3e online). As these mice are highly dyslipidemic, 
we wanted to test whether this severely increased plasma cholesterol content per se would be 
reflected by an enhanced lymphatic transport defect. To test this, we have measured lymphatic 
function in both young (3-month-old) preatherosclerotic Ldlr-/-; hApoB100+/+ mice and Ldlr-/- 
mice. As total cholesterol content of Ldlr-/- mice is known to be half the concentration 
retrieved in the Ldlr-/-; hApoB100+/+ mice (~200 mg/ml vs. ~700 mg/ml)37,39,40, one could 
expect to see an even more impaired lymphatic function in the latter group. However, as a 
premise of the effect of LDLR per se on lymphatic function as a proatherosclerotic factor, we 
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observed no significant difference between the two groups (Fig. 4a). Furthermore, lymphatic 
dysfunction became even more apparent (p<0.05, at 12 mo) throughout atherosclerosis 
progression (Fig. 4b). Just like in apoE-/- mice in which dermal lymphatic vessel diameter 
increases in conjunction with dyslipidemia34, aging Ldlr-/-; hApoB100+/+ mice displayed 
enlarged initial lymphatic vessels (Fig. 4e, p<0.0001, between 6- to 12-month), increased total 
Lyve-1+ area (Fig. 4f, p<0.001, at 12-month) and decreased Lyve-1+ vessels number. As 
mentioned previously, in contrast to Pcsk9-/- mice (Fig. 1a), Ldlr-/-; hApoB100+/+ mice 
demonstrated interrupted EB dye presence (red arrows), as well as extravasated dye from these 
vessels (yellow arrows). This further supported our showcased lymphatic impairment 
following FITC painting, and was also a first indication of collecting vessel malfunction. As 
Pcsk9-/- mice abundant in LDLR display improved lymphatic transport and as 3 month-old 
pre-atherosclerotic Ldlr-/-; hApoB100+/+ mice lacking LDLR already showed a lymphatic 
dysfunction that was exacerbated in parallel to lesion formation, these results reinforce the 
idea that the LDLR per se could play a direct role on lymphatic function.  
 
VEGF-C 152s treatment rescues lymphatic function in young preatherosclerotic Ldlr-/-; 
hApoB100+/+ mice 
VEGF-C was proven to reverse hypercholesterolemia-associated lymphatic dysfunction 
in apoE-/- mice, and to stimulate lymphatic pumping ex vivo in a model of rat mesenteric 
lymphatics by a VEGF receptor-3-dependent mechanism27. Therefore, as our results pointed 
out that LDLR mediated-lymphatic function modulation, at least through PCSK9 variation, 
would most likely be due to an effect on lymphatic collecting vessels, we then investigated 
whether and how lymphatic dysfunction can be restored in young Ldlr-/-; hApoB100+/+ mice. 
VEGF-C 152s is a point mutant that only binds to and activates signaling through VEGFR-3, 
and unlike wild type VEGF-C, is unable to bind VEGFR-2. VEGF-C treatment has previously 
been shown to restore lymphatic function in mice with established atherosclerosis41, and we 
herein aimed to assess whether treatment with VEGF-C 152s could rescue lymphatic function 
before the onset of atherosclerosis in 3-month-old pre-atherosclerotic Ldlr-/-; hApoB100+/+ 
mice. Following treatment, a significant (p<0.001) increase in lymphatic cellular transport was 
observed (Fig. 5c), despite no difference seen in dextran-Cy5 absorption by the initial 
lymphatics (Fig. 5d). Furthermore, when assessing the number of Lyve-1+ vessels in the 
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adventitia of the aortic sinus (Fig. 5a), a significant (p<0.05) increase when compared to 
control (PBS-treated) mice was observed (Fig. 6b). Lastly, in order to exclude the fact that 
VEGF-C could have decreased total plasma cholesterol (TPC) and subsequently improved 
lymphatic function, TPC was measured in VEGF-C 152s treated Ldlr-/-; hApoB100+/+ mice 
versus controls (PBS treated Ldlr-/-; hApoB100+/+). Unexpectedly, our results showed that 
TPC in our PBS-treated Ldlr-/-; hApoB100+/+ was even significantly higher in VEGF-C-treated 
mice versus PBS-treated mice (Fig. 5e).  
 
 
Discussion 
 
Based on original data from the Framingham Study indicating that low plasma levels of 
HDL-C are associated with premature CAD42, increasing levels of HDL has become an 
approach of great interest in research aiming at better controlling related pathologies such as 
atherosclerosis. However, recent resulting conclusions have met with disappointing clinical 
outcomes, emphasizing that atherosclerosis is a multifactorial disease and that many different 
avenues need to be considered in order to better control the atherosclerotic process and to 
prevent CAD. In the past decade, tremendous progress has been made to better characterize 
the interplay between the lymphatic network and chronic inflammatory diseases41, including 
atherosclerosis43. Studies analyzing the morphology of lymphatic vessels in the artery wall 
allowed for insights into their associations with atherosclerosis. In animal models, lymphatic 
vessels have been observed in the adventitia of the artery wall44. In fact, Xu et al. 
demonstrated the presence of lymphatic vessels within the adventitia of the artery wall to be 
an important factor for the draining of local inflammatory cells and cytokines from peripheral 
tissues45. In a clinical setting, Drozdz et al. took interest in the presence of lymphatics in the 
adventitia of the internal carotid artery in humans and showed that the number of adventitial 
lymphatic vessels increases with the severity of atherosclerosis measured as intimal 
thickness46. Along the same path, Vuorio et al. recently published that lymphatic impairment 
worsened the atherosclerosis plaque formation in atherogenic LDLR-/-/ApoB100/100 mice 
crossed with transgenic mice having lymphatic localized insufficiency, and analyzed the 
effects of the absence of lymphatics on lipoprotein metabolism and atherosclerosis47. This 
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group observed a positive correlation between increased atheroma formation and the absence 
of lymphatic vessels. It is now well established that lymphatic vessels are more abundant in 
the adventitial layer of the arterial walls in both animals and humans48.  
 
With this perspective, we here combine recent knowledge governing the identification of 
two attractive new therapeutic targets in atherosclerosis, and sought to characterize their 
possible interaction with the ultimate goal of limiting the disastrous consequences related to 
this pathology. PCSK9 has emerging therapeutic roles in dyslipidemia-associated diseases, 
particularly atherosclerosis and new evidence shows that LVs play a key role in controlling 
cholesterol efflux from peripheral tissues, such as the atherosclerotic lesion21. In this study, we 
aimed to better delineate the effects of the modulation of LDLR, particularly through PCSK9 
inflection, on lymphatic function. Our results suggest for the first time that the absence of 
PCSK9 is associated with improved lymphatic function, most likely targeting the collector 
segment of the vessel. Lymphatic collecting vessel function is disturbed at a very early stage 
before the onset of atherosclerosis and linked to LDLR absence, and this defective transport 
can be prevented by enhancing VEGF-C/VEGFR-3 specific binding. Although the related 
specific mechanisms remain to be understood, our data suggest that LDLR per se could have a 
functional role in the early stage of lymphatic dysfunction, thus corroborating a pleiotropic 
effect of PCSK9 inhibition in atheroprotection.  
 
On top of its positive effect on plasma cholesterol uptake by LDLR, our results suggest 
that lymphatic function also greatly benefits from downregulation of PCSK9. The limited 
subcutaneous adipose tissue accumulation we observed in Pcsk9-/- mice opposes the increased 
visceral adipogenesis previously reported that is most likely due to VLDLR49 and/or CD3616, 
and their role in TG regulation. Whereas the regulation of the latter could be considered in our 
findings, we cannot exclude a potential role of the lymphatic vessels in the clearance process 
of the adipose tissue in peripheral sites, such as the skin. Using two independent techniques, 
our first set of results demonstrate that lymphatic function is enhanced in Pcsk9-/- mice, when 
compared to WT mice. This effect peaks on the 6th month of age, and seems to diminish by the 
12th month, suggesting that PCSK9 inhibition could abrogate the aging-related lymphatic 
dysfunction up to a certain stage. It was recently documented by Dixon’s group that a 
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preferential drainage pattern in lymphatic vessels is possible through what they call “dominant 
vessels”, and in a smaller proportion in “non-dominant vessels”32. They bring forward the 
interesting hypothesis that dominant vessels are driven by extrinsic factors, while non-
dominant vessels are under the influence of intrinsic contraction. Our EB technique further 
supports this affirmation, as illustrated (Fig. 1a). PCSK9 may act upon LDLR present on 
lymphatic collecting vessels, leading to a cellular signaling pathway that modulates the 
capacity of these collectors to properly contract. Along these same lines, we believe PCSK9 
may both have a similar effect and also disturb the anti-atherogenic properties of LECs, such 
as the modulation of eNOs and prostacyclin production, as well as levels of oxidative stress. 
As NO produced by the endothelium acts as a vasoactive agent that modulates Ca2+ release 
and uptake to control lymphatic contraction frequency50, we are aiming to study in further 
details the Ca2+ fluxes and NO production patterns in our atherosclerosis-prone and protected 
mice. As aging is a potential player in lymphatic dysfunction51, the tendency of losing their 
protective effect by 12 months of age could thus be attributable to this factor. Pcsk9-/- mice 
exhibit normal initial lymphatics, with no visible changes seen in the morphology and number, 
at any age. Since at the initial lymphatic level no changes were observed, despite the 
improvement in dendritic cell transport and EB dye, we believe modifications due to LDLR 
enhancement may originate in the collecting vessels. Subsequently, it was necessary to 
demonstrate the ubiquitous nature of LDLR by assessing its presence on endothelial lymphatic 
collecting vessel cells. Despite a reduced lymph flow, Le May et al. observed that PCSK9 
expression impacts postprandial triglyceridemia52, another important cardiovascular risk 
factor. As they observed an increased presence of LDLR in the intestines, it should be taken 
into consideration that there might be an increase of LDLR at the surface of the lacteal vessels 
(intestine lymphatic vessels) thus playing a role in lymphatic transport per se.  
 
Although plaque development becomes apparent only by the age of 4 to 6 months53 in the 
Ldlr-/-; hApoB100+/+ mouse model, we observed lymphatic dysfunction as early as in 3-month 
old mice, before any sign of lesion formation. In parallel, lymphatic dysfunction and 
atherosclerosis continues to worsen in concert with age. Contrarily, when assessing capillary 
functionality in 3-month old pre-atherosclerotic mice by a molecular absorption technique 
(Cy5-Dextran), no differences in molecular lymphatic transport were noted. For that reason, 
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similar to the Pcsk9-/- mouse model, we went on to investigate the morphology and number of 
the initial lymphatics present in the ear dermis, and observed a decrease in their number, 
which we assume to be age-related51. However, their diameter is significantly increased by the 
age of 12 months. This could be due to lymphatic capillary hyperplasia, not consequent of a 
change in their morphology, but rather, due to a dysfunction at the collecting vessels level. As 
these initial vessels are larger, they occupy more space in the dermis, despite their decrease in 
number. Our results are further supported by systemic lymphatic hyperplasia of the initial 
lymphatics in hypercholesterolemic apoE−/− mice34. As observed in atherosclerosis, 
lymphedema is characterized by inflammation, fibrosis, and adipose deposition54. All these 
adverse events, together with the added effects of aging in lymphatic collectors51, cause 
impairment in lymph transport, fluid homeostasis and pathogen clearance55. One thing is 
definite; LDLR and PCSK9 may play a crucial role in better understanding this impairment, 
and emphasizing the need for further studies. Both models offer great insight into potential 
atherosclerosis treatments. While PCSK9 biology has demonstrated a significant new way of 
offering protection against CAD, Ldlr-/-; hApoB100+/+ mice present a humanized 
atherosclerosis-prone model that aids the study of the progression of atherosclerosis, and even 
its potential prevention, as seen with VEGF-C 152s.  
 
The potential predisposition to development of atherosclerosis, seen in Ldlr-/-; 
hApoB100+/+ mice suggests the use of VEGF-C 152s, which selectively binds solely to 
VEGFR-3, as a therapeutic alternative. VEGF-C has been shown to reduce lymphedema by 
stimulating lymphangiogenesis29,30,56. Indeed, we report here that the defect observed in cell 
migration through the lymphatics is significantly improved following treatment with the 
mutant form of VEGF-C, VEGF-C 152s, in young pre-atherosclerotic mice. This could be 
explained by the fact that physiologically, VEGF-C may either enhance lymphangiogenesis or 
stimulate lymphatic pumping, which is a more recent concept27. Several in vitro studies have 
revealed that VEGF-C/VEGFR-3 binding on LEC induces activation of PI3K/Akt and results 
in phosphorylation of eNOS30. Like VEGF, VEGF-C has vasoactive- and endothelial barrier-
altering properties57-59, and it has recently been shown that its binding to VEGFR-3 can alter 
the intrinsic and phasic pumping of collecting LVs27. VEGF-C stimulates lymphatic pumping 
ex vivo in a model of rat mesenteric lymphatics27. Therefore, we believe that the impairment of 
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lymphatic transport, which occurs even before the onset of atherosclerosis, is potentially 
attributable to the contractile capacity of the collecting LVs. Since it has been well established 
that hypercholesterolemia impairs lymphatic function34, it was important to demonstrate that 
the impaired lymphatic function observed in Ldlr-/-; hApoB100+/+ mice was not only due to 
hypercholesterolemia, but also due to a lack of LDLR per se. Three-month-old Ldlr-/- mice 
have a TPC that ranges between 200 to 370 mg/dl37,39,40, whereas TPC of the Ldlr-/-; 
hApoB100+/+ mice included herein, whether treated with VEGF-C 152s or not, is much higher 
(1170 or 860 mg/dl, respectively). Despite this major difference in cholesterol levels, both 3-
month old Ldlr-/- and Ldlr-/-; hApoB100+/+ mice show similar impairment in lymphatic 
transport. Furthermore, regardless of the increase in plasma cholesterol observed in VEGF-C 
treated Ldlr-/-; hApoB100+/+ mice, lymphatic function was significantly improved compared to 
control (PBS treated Ldlr-/-; hApoB100+/+ mice). Once again, this shows that in the context of 
atherosclerosis, hypercholesterolemia is not the sole player affecting lymphatic function.  
 
Taken together, our results suggest for the first time that the absence of PCSK9 is 
associated with improved lymphatic function. Lymphatic collecting vessel function is 
disturbed at a very early stage before any sign of atherosclerotic lesion formation, and this 
defect can be prevented by systemic VEGF-C treatment. We believe that our report reveals 
new important information regarding the specific interactions between the lymphatic system 
and cardiovascular diseases, thus opening doors to potential therapeutic targets for the 
prevention and treatment of atherosclerosis.  
 
 
Materials and Methods 
 
Mice. C57BL/6 wild-type (WT) and Pcsk9-/- mice (backcrossed against C57BL/6 for 10 
generations at our facility) were from Jackson Laboratories. A knockout/transgenic 
dyslipidemic LDLR-/-; hApoB+/+ (ATX) mouse colony was established by one of our 
collaborators at the Montreal Heart Institute (Dr. Éric Thorin)36,37. All experiments were 
carried out on 3-, 6- and 12- month-old male and female mice. Differences between sexes 
were not observed. Animals were housed in a pathogen-free environment under a 12 hour 
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light-dark cycle with free access to water and to standard chow diet. Mice were euthanized 
with CO2 and perfused with 15 ml phosphate buffered-saline (PBS). All experiments were 
performed in accordance with the Canadian Council on Animal Care guidelines and approved 
by the Montreal Heart Institute Animal Care Committee. 
 
Experimental setup. Lymph nodes (LNs), ears, aortas, hearts and popliteal lymphatic 
collecting vessels were harvested and either freshly processed for flow cytometry analysis 
and/or western blots, or fixed in 4% paraformaldehyde (PFA) for future analysis, as described 
below. In some experiments, three month-old ATX mice received an intraperitoneal cavity 
injection of 25 ng VEGF-C 152s (purified recombinant Rat VEGFC protein (152s), 
Fitzgerald) dissolved in PBS, three times a week for 4 weeks. The control group received PBS 
alone.  
 
Lymphatic Functional Assessment. Lymphatic function was first assessed by quantifying the 
dermal clearance of dextran by the initial lymphatics, as described previously60. Briefly, a total 
of 1 µl fluorescent (Cy5) dextran (70 kDa) at a concentration of 2 mg/ml in sterile PBS was 
injected intradermally in the ear pinnae of anesthetized mice. Due to its large size, the tracer is 
specifically uptaken by blind-ended lymphatic capillaries avoiding absorption by blood 
capillaries. Fluorescence decay was observed through the skin using a fluorescence 
stereomicroscope (Leica M205) and images of the skin were acquired every minute for 30 
minutes. The rate of clearance was determined by calculating the area under the curve (AUC) 
of fluorescence intensity at each time point, and normalized to the initial value. The 
normalized rate of fluorescence decay was then calculated from the slope of AUC vs. time, 
which is considered proportional to the actual rate of Cy5-dextran clearance. Second, 
lymphatic function was also assessed using Evans blue dye for tracing popliteal lymphatic 
vessels61. Mice were anesthetized with isoflurane and following Evans Blue intradermal 
injection in the footpad, popliteal lymphatic collecting vessels were visualized using a Stereo 
Discovery V8 microscope (Zeiss). Third, migration of dendritic cell to LN was evaluated after 
epicutaneous application of a FITC solution as described previously62. The animals were 
sacrificed 18 hours later and corresponding skin-draining LNs were recovered and 
enzymatically digested with collagenase D for 25 min at 37°C. Cells were then passed through 
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a 70 μm cell strainer, washed, counted, and stained for analysis by flow cytometry (BD 
Biosciences LSR II). Conjugated antibodies CD11b PerCp-Cy5.5, CD11c PeCy7 and CD45-
APC were used (BioLegend). 
 
Primary mouse lymphatic endothelial cell immunofluorescence and immunoblotting analysis. 
Popliteal lymphatic collecting vessels were identified following Evans blue intradermal 
injection as described above, and harvested. For analysis of LDLR expression on mouse 
primary lymphatic endothelial cells, popliteal lymphatic collecting vessels were digested and 
proteins were extracted following incubation with radioimmunoprecipitation assay (RIPA) 
buffer containing protease and phosphatase inhibitors. Proteins from lymphatic collecting 
vessels (30 µg) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by its transfer to nitrocellulose membranes. The 
membranes were blocked with 5% nonfat dry milk for 1 hour at room temperature. 
Membranes were incubated with an antibody against LDLR (Novus Biologicals) overnight at 
4oC, and HRP-conjugated secondary antibodies were used for detection using the Western 
Lightning Ultra chemiluminescence kit (PerkinElmer). Experiments were performed by 
pooling of 3 to 4 mice per experimental group. The presence of LDLR was also confirmed on 
isolated popliteal lymphatic collecting vessels of mice by whole-mount immunofluorescence 
analysis following incubation with anti-podoplanin (Angio Bio Co.) and anti-LDLR 
antibodies. Images were acquired with an LSM 710 Confocal Microscope (Zeiss) equipped 
with a 63x/1.4 oil dic objective. Images were deconvolved using a theoretical point spread 
function and Huygens Professional software (Scientific Volume Imaging) and volumes were 
rendered using the surface renderer option.  
 
Quantiﬁcation of initial lymphatic density. Hearts and aortae were removed and fixed in 
4% PFA for 2 hours. Hearts were transferred into PBS containing 30% sucrose (wt/vol) 
overnight at 4°C before being immersed in OCT compound and stored at -80°C. Eight-
micrometer-thick cryosections of the aortic sinus were prepared. Cross-sections of the 
aortic sinus were stained with anti-LYVE-1 (ABCAM) and anti-CD68 (Biolegend) antibodies, 
and then incubated with the appropriate secondary antibodies. As macrophages can also be 
positive for LYVE-1, adventitial lymphatic capillaries were identified as LYVE-1+CD68- cells 
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forming vessel-like shapes. Whole-mount immunohistochemical analysis of the ear dermis to 
visualize lymphatic vessels was performed as described previously34. Ear dermis were stained 
for lymphatic capillaries (anti-LYVE-1, ABCAM) at 4°C, and then sections were incubated 
with Alexa Fluor 647 conjugated donkey anti-rabbit antibody and Cy3 donkey anti-rat 
(Jackson ImmunoResearch). All imaging was performed on a Fluoview FV10i microscope 
(Olympus). All vessel counts were performed by one observer. The relative quantification of 
the number of lymphatic capillaries (LYVE-1+ vessels), their diameter and the total surface 
area they occupy was determined by computer-assisted morphometric analysis. Neutral lipid 
assessment in atherosclerotic lesions was performed by Oil-red-O (ORO) staining (Sigma). 
 
Immunohistochemistry. The back skin of the animals was shaved and harvested, fixed in 10% 
formalin, and embedded in paraffin. Eight-micrometer thick back-skin sections were stained 
with hematoxylin and eosin (H&E).  Pictures were taken with an Olympus B45 microscope 
and visualized using ImagePro Plus 7.0 software.  All image handling was performed using 
ImageJ software. 
 
Plasma cholesterol quantitation. Blood was collected into heparin-containing tubes by cardiac 
puncture and plasma was obtained following centrifugation at 2400g for 10 minutes. To avoid 
thawing-related damage on lipoprotein conformation, 5% sucrose (in PBS) was added before 
samples were frozen. Total plasma cholesterol was measured using a Wako kit, according to 
manufacturer instructions (Wako).  
 
Statistics. Data are expressed as the mean ± SEM. Statistical differences were assessed using a 
two-tailed non-parametric Student’s t test, unless otherwise stated, with p < 0.05 reported as 
statistically significant, using Prism software version 6.0c (GraphPad). All experiments 
contained three or more replicate mice per experimental parameter. 
 
 
 
 
 
 38 
Acknowledgements: 
 
We would like to thank Louis Villeneuve for his help with the microscopy imaging, 
Geneviève Collin for her technical help, Dr. Mary Sorci-Thomas for critical reading of the 
manuscript, and Dr. Éric Thorin for the Ldlr-/-; hApoB100+/+ mice used in our studies.  
 
Author contributions statement 
 
AM and CM designed and carried out experiments, analyzed data, and wrote the 
manuscript. FD carried out experiments and GM contributed to design of experiments and 
revised the manuscript. 
 
Competing financial interests 
 
The authors declare no competing financial interests. This work was partially supported 
by the Montreal Heart Institute Foundation (CM, GM), the Banting Research Foundation 
(CM) and the Canadian Institutes of Health Research (CIHR) (MOP133598) (GM). The 
authors have no other relevant affiliations or financial involvement with any organization or 
entity with a financial interest in or financial conflict with the subject matter or materials 
discussed in the manuscript apart from those disclosed. 
 
References 
 
1 Linton, M. F., Babaev, V. R., Gleaves, L. A. & Fazio, S. A direct role for the 
macrophage low density lipoprotein receptor in atherosclerotic lesion formation. J Biol 
Chem 274, 19204-19210 (1999). 
2 Rader, D. J., Cohen, J. & Hobbs, H. H. Monogenic hypercholesterolemia: new insights 
in pathogenesis and treatment. J Clin Invest 111, 1795-1803, doi:10.1172/JCI18925 
(2003). 
3 Soutar, A. K. & Naoumova, R. P. Mechanisms of disease: genetic causes of familial 
hypercholesterolemia. Nature clinical practice. Cardiovascular medicine 4, 214-225, 
doi:10.1038/ncpcardio0836 (2007). 
 39 
4 Herijgers, N., Van Eck, M., Groot, P. H., Hoogerbrugge, P. M. & Van Berkel, T. J. 
Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion 
formation in C57Bl/6 mice. Arterioscler Thromb Vasc Biol 20, 1961-1967 (2000). 
5 Go, G. W. & Mani, A. Low-density lipoprotein receptor (LDLR) family orchestrates 
cholesterol homeostasis. Yale J Biol Med 85, 19-28 (2012). 
6 Goldstein, J. L. & Brown, M. S. Molecular medicine. The cholesterol quartet. Science 
292, 1310-1312 (2001). 
7 Horton, J. D., Cohen, J. C. & Hobbs, H. H. Molecular biology of PCSK9: its role in 
LDL metabolism. Trends Biochem Sci 32, 71-77, doi:10.1016/j.tibs.2006.12.008 
(2007). 
8 Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and 
identification of a compound heterozygote. Am J Hum Genet 79, 514-523, 
doi:10.1086/507488 (2006). 
9 Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr. & Hobbs, H. H. Sequence variations in 
PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354, 
1264-1272, doi:10.1056/NEJMoa054013 (2006). 
10 Glomset, J. A. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9, 
155-167 (1968). 
11 Temel, R. E. & Brown, J. M. Biliary and nonbiliary contributions to reverse 
cholesterol transport. Curr Opin Lipidol 23, 85-90, 
doi:10.1097/MOL.0b013e3283508c21 (2012). 
12 Investigators, A.-H. et al. Niacin in patients with low HDL cholesterol levels receiving 
intensive statin therapy. N Engl J Med 365, 2255-2267, doi:10.1056/NEJMoa1107579 
(2011). 
13 Schwartz, G. G. et al. Rationale and design of the dal-OUTCOMES trial: efficacy and 
safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 158, 
896-901 e893, doi:10.1016/j.ahj.2009.09.017 (2009). 
14 Tardif, J. C. et al. Effects of the high-density lipoprotein mimetic agent CER-001 on 
coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. 
Eur Heart J 35, 3277-3286, doi:10.1093/eurheartj/ehu171 (2014). 
15 Everett, B. M., Smith, R. J. & Hiatt, W. R. Reducing LDL with PCSK9 Inhibitors - 
The Clinical Benefit of Lipid Drugs. N Engl J Med 373, 1588-1591, 
doi:10.1056/NEJMp1508120 (2015). 
16 Demers, A. et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty 
Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. 
Arterioscler Thromb Vasc Biol, doi:10.1161/ATVBAHA.115.306032 (2015). 
17 Sun, X. et al. Proprotein convertase subtilisin/kexin type 9 deficiency reduces 
melanoma metastasis in liver. Neoplasia 14, 1122-1131 (2012). 
18 Sharotri, V., Collier, D. M., Olson, D. R., Zhou, R. & Snyder, P. M. Regulation of 
epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 
(PCSK9). J Biol Chem 287, 19266-19274, doi:10.1074/jbc.M112.363382 (2012). 
19 Tavori, H., Giunzioni, I. & Fazio, S. PCSK9 inhibition to reduce cardiovascular 
disease risk: recent findings from the biology of PCSK9. Curr Opin Endocrinol 
Diabetes Obes 22, 126-132, doi:10.1097/MED.0000000000000137 (2015). 
20 Giunzioni, I. et al. Local Effects of Human PCSK9 on the Atherosclerotic Lesion. The 
Journal of pathology, doi:10.1002/path.4630 (2015). 
 40 
21 Martel, C. et al. Lymphatic vasculature mediates macrophage reverse cholesterol 
transport in mice. J Clin Invest 123, 1571-1579, doi:10.1172/JCI63685 (2013). 
22 Lim, H. Y. et al. Lymphatic vessels are essential for the removal of cholesterol from 
peripheral tissues by SR-BI-mediated transport of HDL. Cell Metab 17, 671-684, 
doi:10.1016/j.cmet.2013.04.002 (2013). 
23 Tammela, T. & Alitalo, K. Lymphangiogenesis: Molecular mechanisms and future 
promise. Cell 140, 460-476, doi:10.1016/j.cell.2010.01.045 (2010). 
24 Jeltsch, M. et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. 
Science 276, 1423-1425 (1997). 
25 Baluk, P. et al. Functionally specialized junctions between endothelial cells of 
lymphatic vessels. J Exp Med 204, 2349-2362, doi:10.1084/jem.20062596 (2007). 
26 von der Weid, P. Y. & Zawieja, D. C. Lymphatic smooth muscle: the motor unit of 
lymph drainage. Int J Biochem Cell Biol 36, 1147-1153, 
doi:10.1016/j.biocel.2003.12.008 (2004). 
27 Breslin, J. W. et al. Vascular endothelial growth factor-C stimulates the lymphatic 
pump by a VEGF receptor-3-dependent mechanism. Am J Physiol Heart Circ Physiol 
293, H709-718, doi:10.1152/ajpheart.00102.2007 (2007). 
28 Davis, M. J., Lane, M. M., Scallan, J. P., Gashev, A. A. & Zawieja, D. C. An 
automated method to control preload by compensation for stress relaxation in 
spontaneously contracting, isometric rat mesenteric lymphatics. Microcirculation 14, 
603-612, doi:10.1080/10739680701436152 (2007). 
29 Goukassian, D. A. et al. Engineering the response to vascular injury: divergent effects 
of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells 
result in endothelial recovery and inhibition of neointimal growth. Circ Res 93, 162-
169, doi:10.1161/01.RES.0000082980.94211.3A (2003). 
30 Joukov, V. et al. A recombinant mutant vascular endothelial growth factor-C that has 
lost vascular endothelial growth factor receptor-2 binding, activation, and vascular 
permeability activities. J Biol Chem 273, 6599-6602 (1998). 
31 von der Weid, P. Y., Lee, S., Imtiaz, M. S., Zawieja, D. C. & Davis, M. J. 
Electrophysiological properties of rat mesenteric lymphatic vessels and their regulation 
by stretch. Lymphat Res Biol 12, 66-75, doi:10.1089/lrb.2013.0045 (2014). 
32 Weiler, M. & Dixon, J. B. Differential transport function of lymphatic vessels in the rat 
tail model and the long-term effects of Indocyanine Green as assessed with near-
infrared imaging. Front Physiol 4, 215, doi:10.3389/fphys.2013.00215 (2013). 
33 Angeli, V. et al. Dyslipidemia associated with atherosclerotic disease systemically 
alters dendritic cell mobilization. Immunity 21, 561-574, 
doi:10.1016/j.immuni.2004.09.003 (2004). 
34 Lim, H. Y. et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and 
degeneration. Am J Pathol 175, 1328-1337, doi:10.2353/ajpath.2009.080963 (2009). 
35 Milasan, A., Ledoux, J. & Martel, C. Lymphatic network in atherosclerosis: the 
underestimated path. Future Science OA 1, 1-10, doi:10.4155/fso.15.61 (2015). 
36 Bolduc, V. et al. Heart rate-associated mechanical stress impairs carotid but not 
cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart 
Circ Physiol 301, H2081-2092, doi:10.1152/ajpheart.00706.2011 (2011). 
 41 
37 Gendron, M. E. et al. Late chronic catechin antioxidant treatment is deleterious to the 
endothelial function in aging mice with established atherosclerosis. Am J Physiol Heart 
Circ Physiol 298, H2062-2070, doi:10.1152/ajpheart.00532.2009 (2010). 
38 Drouin, A. et al. Catechin treatment improves cerebrovascular flow-mediated dilation 
and learning abilities in atherosclerotic mice. Am J Physiol Heart Circ Physiol 300, 
H1032-1043, doi:10.1152/ajpheart.00410.2010 (2011). 
39 Laurila, A. et al. High-fat, high-cholesterol diet increases the incidence of gastritis in 
LDL receptor-negative mice. Arterioscler Thromb Vasc Biol 21, 991-996 (2001). 
40 Hasty, A. H. et al. Severe hypercholesterolemia, hypertriglyceridemia, and 
atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J 
Biol Chem 276, 37402-37408, doi:10.1074/jbc.M010176200 (2001). 
41 D'Alessio, S. et al. VEGF-C-dependent stimulation of lymphatic function ameliorates 
experimental inflammatory bowel disease. J Clin Invest 124, 3863-3878, 
doi:10.1172/JCI72189 (2014). 
42 Castelli, W. P. et al. HDL cholesterol and other lipids in coronary heart disease. The 
cooperative lipoprotein phenotyping study. Circulation 55, 767-772 (1977). 
43 Llodra, J. et al. Emigration of monocyte-derived cells from atherosclerotic lesions 
characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 101, 
11779-11784, doi:10.1073/pnas.0403259101 (2004). 
44 Johnson, R. A. Lymphatics of blood vessels. Lymphology 2, 44-56 (1969). 
45 Xu, X., Lin, H., Lv, H., Zhang, M. & Zhang, Y. Adventitial lymphatic vessels -- an 
important role in atherosclerosis. Med Hypotheses 69, 1238-1241, 
doi:10.1016/j.mehy.2007.04.007 (2007). 
46 Drozdz, K. et al. Adventitial lymphatics and atherosclerosis. Lymphology 45, 26-33 
(2012). 
47 Vuorio, T. et al. Lymphatic vessel insufficiency in hypercholesterolemic mice alters 
lipoprotein levels and promotes atherogenesis. Arterioscler Thromb Vasc Biol 34, 
1162-1170, doi:10.1161/ATVBAHA.114.302528 (2014). 
48 Kutkut, I., Meens, M. J., McKee, T. A., Bochaton-Piallat, M. L. & Kwak, B. R. 
Lymphatic vessels: an emerging actor in atherosclerotic plaque development. Eur J 
Clin Invest 45, 100-108, doi:10.1111/eci.12372 (2015). 
49 Roubtsova, A. et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) 
regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. 
Arterioscler Thromb Vasc Biol 31, 785-791, doi:10.1161/ATVBAHA.110.220988 
(2011). 
50 Cohen, R. A. et al. Mechanism of nitric oxide-induced vasodilatation: refilling of 
intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-
operated Ca2+ influx. Circ Res 84, 210-219 (1999). 
51 Karaman, S. et al. Decline of lymphatic vessel density and function in murine skin 
during aging. Angiogenesis 18, 489-498, doi:10.1007/s10456-015-9479-0 (2015). 
52 Le May, C. et al. Proprotein convertase subtilisin kexin type 9 null mice are protected 
from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 29, 684-690, 
doi:10.1161/ATVBAHA.108.181586 (2009). 
53 Farhat, N. et al. Angiopoietin-like 2 promotes atherogenesis in mice. J Am Heart Assoc 
2, e000201, doi:10.1161/JAHA.113.000201 (2013). 
 42 
54 Ghanta, S. et al. Regulation of inflammation and fibrosis by macrophages in 
lymphedema. Am J Physiol Heart Circ Physiol 308, H1065-1077, 
doi:10.1152/ajpheart.00598.2014 (2015). 
55 Zolla, V. et al. Aging-related anatomical and biochemical changes in lymphatic 
collectors impair lymph transport, fluid homeostasis, and pathogen clearance. Aging 
Cell 14, 582-594, doi:10.1111/acel.12330 (2015). 
56 Saaristo, A. et al. Vascular endothelial growth factor-C gene therapy restores 
lymphatic flow across incision wounds. FASEB J 18, 1707-1709, doi:10.1096/fj.04-
1592fje (2004). 
57 Wu, H. M., Huang, Q., Yuan, Y. & Granger, H. J. VEGF induces NO-dependent 
hyperpermeability in coronary venules. Am J Physiol 271, H2735-2739 (1996). 
58 Mayhan, W. G. VEGF increases permeability of the blood-brain barrier via a nitric 
oxide synthase/cGMP-dependent pathway. Am J Physiol 276, C1148-1153 (1999). 
59 Aramoto, H., Breslin, J. W., Pappas, P. J., Hobson, R. W., 2nd & Duran, W. N. 
Vascular endothelial growth factor stimulates differential signaling pathways in in vivo 
microcirculation. Am J Physiol 287, H1590-1598, doi:10.1152/ajpheart.00767.2003 
(2004). 
60 Platt, A. M. et al. Normal dendritic cell mobilization to lymph nodes under conditions 
of severe lymphatic hypoplasia. J Immunol 190, 4608-4620, 
doi:10.4049/jimmunol.1202600 (2013). 
61 Scallan, J. P., Hill, M. A. & Davis, M. J. Lymphatic vascular integrity is disrupted in 
type 2 diabetes due to impaired nitric oxide signalling. Cardiovasc Res 107, 89-97, 
doi:10.1093/cvr/cvv117 (2015). 
62 Randolph, G. J., Angeli, V. & Swartz, M. A. Dendritic-cell trafficking to lymph nodes 
through lymphatic vessels. Nat Rev Immunol 5, 617-628, doi:10.1038/nri1670 (2005). 
 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 
 
 
 
 
 
 
 51 
3. DISCUSSION 
This Mémoire describes important new findings in an emerging field bridging 
lymphatic function, lipoproteins and atherosclerosis. Our results suggest that lymphatic 
dysfunction is present before the onset of atherosclerosis, and that this dysfunction is primarily 
associated with a defect in the collecting lymphatic vessels, thereby limiting lymph transport 
from peripheral tissues to the blood. Our subsequent work shows that this lack of lymph 
propulsion could be due to the absence of the LDLR, and that lymphatic transport can be 
restored by systemic injections of a VEGFR-3-selective agonist, VEGF-C 152s. Our work 
identifies new potential therapeutic targets for the prevention and treatment of atherosclerosis. 
This opens doors to the possibility of preventive care, in which patients could be screened for 
lymphatic dysfunction and obtain a treatment that could hopefully abrogate atherosclerosis 
development. 
Beginning with the therapeutic potential of the PCSK9 ligand, which at the moment is 
a very prominent subject of interest in the lipoprotein field, we showed that lack of PCSK9 
offers increased protection against atherosclerosis. As our results show, the increased presence 
of LDLR might affect lymphatic function, the nature of which remains to be identified. To our 
knowledge, we are the first to clearly show by immunofluorescence and western blot that 
LDLR is present at the surface of LECs, bringing forth new regulatory possibilities for these 
cells and ultimately, of the lymphatic network as a whole.  
Secondly, we demonstrated that early treatment with VEGF-C 152s is able to rescue 
lymphatic function in pre-atherosclerotic Ldlr-/-; hApoB100+/+ mice. We need to further study 
its long-term effects on plaque regression and better characterize its protective outcome. So 
far, supported by data from the literature, we believe that VEGF-C 152s acts on the capacity of 
collecting lymphatic vessels to contract, rather than by increasing lymphangiogenesis, as its 
primary role may suggest.  
The origin of the lymphatic dysfunction is now better understood in both pre-
atherosclerotic, as well as atherosclerotic mice, as we eliminated the possibility that the 
lymphatic capillaries are a cause of lymphatic impairment. Due to their normal morphology, 
as well as function, clearly demonstrated in our mouse models, our data strongly suggests that 
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a defect predominantly occurs at an upstream level, namely the collecting vessels. Further 
experiments we are currently working on will better delineate this impairment. In the 
following sections I will go into more detail explaining our rationale of the steps we have 
undertaken. 
3.1    Pathophysiology of the lymphatic collecting vessels 
Dysfunction in lymphatic transport is central to numerous pathologies that affect 
millions of people worldwide96. It now comes as no surprise that this impairment could also be 
seen in atherosclerosis. In this project, in order to pinpoint the exact portion (i.e. lymphatic 
capillaries or lymphatic collecting vessels) of the lymphatic vessels that may cause the 
impaired lymph through the lymphatics, we first started looking at the lymphatic capillaries, 
which are easy to study as they are located at the extremity of most tissues. When we looked 
at their morphology (their branch size, diameter, as well as the total surface area they cover) in 
the ear dermis of the mouse, we were unable to see any differences between Pcsk9-/- and Ldlr-/-
; hApoB100+/+ mice, at their respective age. We did however see differences begin to appear 
in Ldlr-/-; hApoB100+/+ mice, as they get older. As it has already been shown that lymphatic 
capillary integrity diminishes with age97, we also performed functional tests using a molecular 
tracer (dextran-Cy5) that is large enough to only be taken up by these lymphatic capillaries (± 
240 μm) , but not able to enter the bloodstream. Once again, our results indicated that, at least 
before the onset of atherosclerosis, the lymphatic capillaries appear to function normally.  
Intrinsic and extrinsic factors can limit lymphatic contraction. Anatomical factors 
include, but are not limited to, the over-accumulation of skin adipose tissue measured in Ldlr-/-
; hApoB100+/+ mice. As previously described, lymphatic collectors are modulated by extrinsic 
factors such as the SMCs that surrounds them. An increase in fat around the vessels, which 
suggests a decrease in the muscle surrounding the vessels, may diminish their contractile 
ability. Furthermore, enlarged adipocytes recruit macrophages and promote inflammation98, 
and collecting lymphatic vessel permeability facilitates adipose tissue inflammation and 
distribution of antigen to lymph nodes99.  However, we see a reduction in lymphatic drainage 
probably due to the production of various mediators associated with inflammation such as the 
production of NO100,101. As seen before, under normal physiological conditions, eNOS is the 
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primary source of NO produced in response to increased shear flow. However, during an 
inflammatory response, NO can also be produced by immune cells surrounding collecting 
lymphatic vessels and in adjacent spaces of the interstitium, via iNOS, independent of the 
endothelium. The resulting excess of NO results in inhibition of the pumping capacity of the 
lymphatics102. Supporting this, Scallan et al73 showed that NO production, whether basal or 
stimulated, depresses murine collecting lymphatic contractile activity. We therefore expect to 
see a disturbance in intracellular Ca2+ and an overproduction of NO in our atherosclerotic 
mouse model.  
Age is a major driving force for change in the body, and so the effect of age on 
lymphatic structure and function should also be taken into consideration. Decreased 
contractility and pumping efficiency, as well as a decrease in extracellular matrix and 
contractile proteins in aged lymphatic collectors, are believed to be physiological changes that 
occur with age103. Furthermore, impaired pathogen clearance, and impaired permeability, 
leading to leakiness in aged collectors, were also seen103.  
When it comes to the role of lymphatics in mRCT, and ultimately atherosclerosis, our 
results indicate that further understanding of the physiological characteristics of lymphatic 
vessel pumping and general dynamics is required. We are currently studying not only the 
contraction capacity of the lymphatics, but also their permeability, valves and endothelial 
junction integrity.  
3.2    Potential treatment using a selective agonist of VEGFR-3 
This part of the project is inspired by promising preliminary results showing treatment 
with VEGF-C 152s, a mutated form of VEGF-C that specifically activates VEGFR-3, restores 
lymphatic molecular transport in the ear dermis of both hypercholesterolemic apoE-/-
 
and Ldlr-
/- mice. Based on these results, we went on to investigate if VEGF-C 152s can rescue 
lymphatic transport in 3-month old Ldlr-/-; hApoB100+/+ mice: at this age these mice show no 
atherosclerotic lesions. We initially examined the molecular transport. We did not see any 
differences following treatment, which we attribute to the fact that at this age, the lymphatic 
capillaries, which are responsible for absorbing the molecular tracer, are seemingly normal. 
However, we were able to see an effect of VEGF-C 152s in 3-month old Ldlr-/-; hApoB100+/+ 
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mice when cellular transport was assessed. Following treatment with VEGF-C 152s, 
lymphatic function was restored. We excluded the fact that VEGF-C could have decreased 
total plasma cholesterol (TPC) and subsequently improved lymphatic function, as TPC was 
significantly higher in VEGF-C-treated mice versus PBS-treated Ldlr-/-; hApoB100+/+ mice. 
This led us to conclude that although VEGF-C promotes lymphangiogenesis, it may actually 
stimulate lymphatic pumping as well. Supporting data from the literature suggest that VEGF-
C increases lymphatic contraction frequency, dilation, and pump flow through its action on 
VEGFR-3. In fact, it is speculated that the lymphatic contractile response to VEGFR-3 
activation involves multiple signalling pathways, such as the release of intracellular Ca2+ 
within LECs and activation of eNOS, to regulate phasic and tonic contractility104. To date, 
VEGF-C/VEGFR-3 binding on LECs has been shown to activate PI3K/Akt and increase the 
phosphorylation of P70S6K, PLCγ1, Erk1/2 and eNOS.  
Inflammation is a critical part of the atherosclerotic process, and studies of VEGF-C in 
inflammatory bowel disease (IBD), a chronic inflammatory disease, could prove to be useful 
in better understanding atherosclerosis. Crohn’s disease, for example, is associated with an 
aberrant mucosal immune response and furthermore, D’Alessio et al. demonstrated that 
adenoviral induction of VEGF-C expression provides marked protection against the 
development of acute and chronic colitis in two different animal models. These authors 
believe that VEGF-C offers protection mediated by ‘resolving macrophages’ in a STAT6-
dependent manner105. STAT6 promotes interleukin-4 (IL4) mediated biological responses, 
which decreases the production of M1 macrophages (pro-inflammatory), thus allowing the 
alternative activation of repair macrophages, M2 (anti-inflammatory)105. This all leads to a 
decrease in pathological inflammation, suggesting that treatment with VEGF-C may serve to 
delay the development and/or progression of atherosclerosis. We now aim to further 
investigate the athero-protective role of VEGF-C in the Ldlr-/-; hApoB100+/+ mouse model of 
atherosclerosis.  
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3.3    LDLR modulation and PCSK9 as a potential therapeutic 
target 
Our results lead us to believe that hypercholesterolemia and/or aging are not the only 
players responsible for the impaired lymphatic transport impairment in atherosclerotic mice. 
As our findings point out, despite the absence of atherosclerotic lesions prior to the onset of 
atherosclerosis, 3-month old Ldlr-/-; hApoB100+/+ mice display a clear defect in cellular 
lymphatic transport. On the contrary, Pcsk9-/- mice display no defects in dendritic cell 
transport through the lymphatics at each age examined and actually displayed enhanced cell 
transport through the lymphatics at 6 months. Gain-of-function mutations in the gene encoding 
PCSK9 are linked to familial hypercholesterolemia106, analogous to LDLR and ApoB. 
Furthermore, studies indicate that PCSK9 might accelerate atherosclerosis by promoting 
inflammation, endothelial dysfunction, and hypertension by mechanisms that are independent 
of the LDLR107. As previously mentioned, PCSK9 enhances LDLR degradation, resulting in 
LDL accumulation in plasma. In fact, the atherosclerosis-protected Pcsk9-/- mice are 
characterized by a 3-fold increased hepatic LDLR levels and 80% decreased plasmatic 
LDL108. Furthermore, Le May et al. observed that PCSK9 expression impacts postprandial 
triglyceridemia109, another important cardiovascular risk factor. As important as the presence 
of LDLR at the surface of hepatocytes is, we found out that it is also on the surface of 
lymphatic endothelial cells from collecting vessels. This new data suggests that modulation of 
LDLR could have a direct effect on lymphatic vessel function. Also, supporting data suggests 
that removal of cholesterol by lymphatic vessels is dependent on the uptake and transcytosis of 
HDL by other receptors such as SR-B1 expressed on lymphatic endothelium110. However, as 
Temel et al. showed that intestinal SR-B1 is not involved in transintestinal cholesterol efflux 
(TICE), we believe that these results need further confirmation111. Nonetheless, as increased 
presence of LDLR was observed in the intestines at the surface of the lacteals109, their 
presence may play a role in lymphatic transport per se. Therefore, we thoroughly believe that 
LDLR plays a functional role at least in the early stage of lymphatic dysfunction in 
atherosclerosis, and that PCSK9 inhibition may exert an additional pleiotropic effect on 
atheroprotection. Many pharmaceutical companies now target PCSK9, but it is also believed 
that its presence in the body is most certainly not coincidental. Although its inhibition offers 
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important control against hypercholesterolemia, which we will continue to investigate, 
especially through the link of the LDLR in conjunction with the lymphatic system, it has been 
shown that upon hepatic damage, patients lacking PCSK9 could be at risk of 
hypercholesterolemia112. Nonetheless, a great deal of emphasis is currently focused on 
blocking PCSK9 with the help of monoclonal antibodies113, and there is even an experimental 
PCSK9 vaccine that induces the body to produce its own anti-PCSK9 antibodies114. 
Furthermore, PCSK9 has been shown to affect the regulation of epithelial Na+ channel (ENaC) 
trafficking and therefore modulate epithelial Na+ absorption, which is critical for blood 
pressure control115. It will be interesting to see if PCSK9 directly modulates Ca2+ channels in 
LECs. Most interestingly, PCSK9 was shown to be expressed endogenously both at the 
mRNA and protein level in murine peritoneal macrophages35, and Fazio et al. showed for the 
first time that this PCSK9 expression directly influences atherosclerotic plaque composition 
with no changes in serum cholesterol levels, suggesting a direct effect of macrophage PCSK9 
in inflammation and plaque development. Therefore, several pros and cons need to be further 
investigated if we are to assure a risk-free potential treatment against naturally occurring 
proteins within our bodies.  
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4. CONCLUSION 
Based on our data and work from other groups, there is accumulating evidence that 
enhancing lymphatic transport could limit atherosclerosis progression and favour plaque 
regression. We have shown that lymphatic transport is impaired in young, atherosclerosis-
prone mice, even before the onset of atherosclerosis. We believe it to be potentially associated 
with a defect in the lymphatic pumping capacity, and we suggest that enhancing VEGF-
C/VEGFR-3 signalling can abolish this specific defect. As LDLR appears to be implicated in 
lymphatic function, we now aim to further study the possible effects of PCSK9 and LDLR 
modulation, in modifying lymphatic activity. 
As the Montreal Heart Institute has a unique infrastructure in Canada to study 
atherosclerosis in clinical settings (i.e. the Pharmacogenomics Center and BioBanque), we are 
eager to pursue translational projects to assess the correlation between lymphatic function and 
atherosclerosis in patients. We are currently optimizing a non-invasive near infrared (NIR) 
imaging technique that detects exogenous indocyanine green (ICG) in the lymphatic vessel, 
following its systemic intradermal injection. Our main goal, with the collaboration of local and 
international experts, is to identify strategies that may enhance lymphatic function and lead to 
the prevention and regression of atherosclerosis.  
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The lymphatic system is a key component of tissue fluid homeostasis. In contrast to 
the closed and high-pressure blood vascular system, the lymphatic vascular system 
transports lymph in an open and low-pressure network. A prerequisite player in the 
transport of immune cells and cholesterol metabolism, it has been understudied until 
recently. Whereas defects in lymph circulation are mostly associated with pathologies 
such as congenital or acquired lymphedema, emerging significant developments are 
unraveling the role of lymphatic vessels in other pathological settings. In the last 
decade, discoveries of underlying genes responsible for developmental and postnatal 
lymphatic growth, combined with state-of-the-art lymphatic function imaging and 
quantification techniques, have matched the growing interest in understanding the 
role of the lymphatic system in atherosclerosis. With a historical perspective, this 
review highlights the current knowledge regarding interaction between the lymphatic 
vascular tree and atherosclerosis, with an emphasis on the physiological mechanisms 
of this multifaceted system throughout disease onset and progression.
The blood and lymphatic vascular systems are parallel but interdependent networks. 
The lymphatic system governs the transport of superfluous interstitial fluids from 
peripheral tissues to the blood circulation, maintaining fluid balance throughout the 
body. Defects in lymphatic function have been broadly associated with pathologies 
such as congenital or acquired lymphedema. Although longstanding observations 
suggested that the lymphatic vasculature could be central in the development of 
chronic inflammatory diseases, recent publications specifically point out its potential 
implication in atherosclerosis. In this review, we highlight the current knowledge 
unraveling the interaction between the lymphatic network and atherosclerosis, with 
an emphasis on the physiological mechanisms of this intricate system.
Keywords: ATHEROSCLEROSIS s LYMPHATIC ENDOTHELIUM s LYMPHATIC SMOOTH MUSCLE CELLS  
s LYMPHATIC VESSELS
In the 1620s, two important circuits of the 
bodies were officially discovered: De Moto 
Cordis and De lactibus sive lacteis venis were 
two independently published manuscripts, 
portraying the blood and the lymphatic cir-
culation, respectively. Albeit interdependent, 
the blood and the lymphatic vascular net-
works are two separate circulatory systems 
running in juxtaposition, having separate, 
but often interdependent, functions [1]. Four 
centuries after their first official identifica-
tion, advances on blood vascular biology far 
surpass those of lymphatic biology. Why has 
there been such a gap in the interest given 
to both particular systems? Whereas tools 
to study the venous and arterial circula-
tion have been developed at a greater pace, 
exploring the lymphatic network had its load 
of difficulties. Until very recently, very few 
methods had been optimized to fully charac-
terize lymphatic function in health and dis-
ease. The urge for a better understanding of 
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this complex system became obvious with the report 
of the ubiquitous presence of those milky-white ves-
sels in nearly all vascularized tissues. Their potential 
association with diverse severe pathologies was then 
clearer. The progress that has been made since the 
turn of the present century is tremendous: new genetic 
mouse models [2,3] and imaging tools [4,5] developed for 
both animals and humans have greatly contributed to 
unraveling the role of the lymphatic system in different 
pathophysiologic conditions even outside of the fields 
of lymphedema, such as in atherosclerosis.
This article highlights recent advances in our under-
standing of the role of the lymphatic vascular tree in 
cardiovascular diseases, with a specific attention to 
atherosclerosis. We place particular emphasis on work 
depicting the functional mechanisms of this complex 
system throughout disease onset and progression.
Historical perspective
In Italy, 23 July 1622, a professor of anatomy and sur-
gery was meticulously practicing vivisection on a dog. 
Gasparo Aselli and a group of colleagues were observ-
ing recurrent nerves in the animal. Subsequently, in an 
attempt to watch the movements of the diaphragm in 
the same operation, he opened the abdomen. Thinking 
he was dealing with nerves belonging to the intestines, 
the Italian described what he saw as ‘(…) cords, exceed-
ingly thin and beautifully white, scattered the whole 
mesentery and the intestine, starting from innumer-
able beginnings.’ [6]. Therefore, in the first published 
color-printed illustrations in a medical or anatomical 
work, Professor Aselli depicted the ‘vessels containing 
white blood’ described by Hippocrates in 400 BC [7] as 
lacteae venae, or ‘milky veins’ [6]. Three decades later, 
Thomas Bartholin created the term ‘lymphatics,’ based 
on his work performed in parallel to the work of others 
on the thoracic duct in the same period (Olaus Rud-
beck, 1630–1702 ; Jean Pecquet, 1624–1674 ; George 
Joyliffe, 1621–1658) [8]. While discoveries of the 17th 
century led to the establishment of the anatomical atlas 
of the lymphatic system, the discoveries from the two 
following century portrayed the network as a passive 
draining network, bringing a first insight on the role 
of the lymphatic system. William and John Hunter 
pioneered the discovery of the absorptive capacity of 
the lymphatics in the 18th century [9], while studies 
on lymph motion through the lymphatic vessels had 
started to emerge in the 19th century. Lymph composi-
tion per se was studied concomitantly, first suggesting 
that lymph is formed as a filtrate of the blood [10]. It 
is in the second end of that century that Rudolf Vir-
chow investigated the role of lymph nodes as filtering 
units [11]. Few decades later, in the early 20th century, 
Florence Rena Sabin brought up the first insight on 
lymphatic development. She innovatively proposed 
lymph sacs originate from endothelial cells that out-
grow from the veins during early development [12]. We 
had to wait for a couple of decades before observing 
lymphatics through lymphography, a method allowing 
the clinical observation of lymphatic disorders [13].
General anatomy & functions of the 
lymphatic vessels
The lymphatic system is now recognized as working 
in close collaboration with the cardiovascular system. 
The lymphatic network is an essential component 
of the immune system, playing major roles in host 
defense and adaptive immunity, as it is the principal 
route of transport from tissues for antigen and immune 
cells [14]. Lymphatic vessels are required for the mainte-
nance of fluid homeostasis within the body [15], absorb-
ing lymph through thin-walled and blind-ended lym-
phatic capillaries (also called initial lymphatics) from 
the peripheral tissue. Initial lymphatics are highly per-
meable and constituted of specialized, discontinuous 
‘button-like’ junctions between endothelial cells [16]. 
Lymphatic capillaries are characterized by an absence 
of smooth muscle cells (SMCs) and specific expression 
of LYVE-1 on the lymphatic endothelial cells (LECs). 
When lymph continues its path from the initial lym-
phatics, it converges into larger precollecting and sub-
sequently collecting lymphatic vessels [15,17]. Collect-
ing vessels are responsible of maintaining lymph flow 
through contraction of units called lymphangions. A 
lymphangion is defined as a vessel segment delimited 
by two endothelial leaflet valves. In the absence of 
strong positive pressure leading the lymph toward the 
vein, these valves allow unidirectional flow in prevent-
ing lymph backflow [16]. A basement membrane, podo-
planin expression, continuous ‘zipper-like’ cell–cell 
junctions and a SMC layer are also distinguishing col-
lecting vessels from lymphatic capillaries. After reach-
ing the lymph nodes (LNs), the afferent collecting 
vessels become the efferent collecting vessels and, ulti-
mately, the collecting lymphatic vessels converge into 
the thoracic duct or the right lymphatic trunk, where 
lymph is finally reaching the venous circulation via the 
subclavian vein [13,14]. In the intestines, the lymphatic 
system is essential as it absorbs lipid through entities 
called lacteals, transporting lipids from the gut into the 
blood [18,19].
Following up on Sabin’s work [12], it has been 
described that venous endothelial cells (VECs) dif-
ferentiation into LEC progenitors from the cardinal 
vein allows lateral sprouting and lymph sacs forma-
tion, the latter being characterized by the expression of 
the transcription factor Prox1 [20]. Prox1+ cells require 
a paracrine VEGF-C gradient to spread away from 
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embryonic veins [21]. Subsequently, the lymph sacs 
undergo extensive remodeling to form a structured 
vascular network. Lymphatic development and regula-
tion are dependent upon VEGF-C/D and its receptor 
VEGFR-3 [22], and Prox1 drives VEGFR-3 expression 
that enables LEC to respond to VEGFR-3 ligands [23].
To properly determine whether lymphatics are active 
players in cardiovascular disease progression or regres-
sion, we must combine morphological observations and 
lymph composition with functional studies. Several 
parameters need to be taken into consideration when 
assessing proper lymphatic function, whether it is at 
a cellular or molecular level, both under physiological 
and pathological conditions.
Lymphatic morphology in atherosclerosis
Lymphatic biology and function in heart disease is 
gaining exponential attention. First studied in the 
fields of lymphedema and cancer, the lymphatic vas-
cular tree is now broadly studied in acute and chronic 
inflammatory diseases. Atherosclerosis is a chronic 
inflammatory disease affecting large- to medium-sized 
arteries, and driven by two main constituents: mac-
rophages and cholesterol. Macrophages accumulate in 
the expanding aortic intima, engulf lipids (becoming 
so-called foam cells) and produce a wide-ranging spec-
trum of inflammatory mediators [24–27]. Macrophage 
reverse cholesterol transport (mRCT) is the mecha-
nism by which cholesterol homeostasis occurs in the 
artery wall, as cholesterol is mobilized from foam cells 
and subsequently transferred from the peripheral tis-
sue to the liver and feces [28], or directly to the fecal 
pathway [29]. Both exit of foam cells and cholesterol 
from the plaques are believed to be essential targets 
in the reduction of atherosclerosis burden, and risk of 
coronary events such as plaque rupture [30].
Surprisingly, despite the well-defined roles of lym-
phatic vessels in preserving fluid balance throughout 
the body by returning plasma proteins from interstitial 
spaces back to the blood circulation, only little atten-
tion has been given yet to the role of the lymphatic 
vasculature in the atherosclerotic process. In the last 
century, only a few avant-garde scientists pointed out 
the concept that lymphatics, and particulary lymph 
flow, could influence atherogenesis [31–33]. In a review 
manuscript published in 1981, Lemole had concat-
enated important publications in which intimal thick-
ening was observed following lymphatic blockade. He 
suggested that enhanced stagnation of the interstitial 
fluid in the arterial wall could be due to lymphostasis, 
phenomenon in which factors that might contribute 
to the development of atherosclerosis, such as intimal 
edema, are present [33]. He concluded by suggesting 
that further studies in immunology, pathology, lipid 
metabolism and nuclear medicine were needed to 
confirm this hypothesis [33]. Thirty years later, several 
original fundamental studies and clinical observations 
have been published in this regard.
Interest to lymphatic biology and function in coro-
nary artery disease is growing exponentially. Morpho-
logical analysis of the lymphatic vessels within the 
arterial wall gave the first insight of the association 
between the lymphatic system and atherosclerosis. In 
animal models, lymphatic vessels have been consis-
tently observed in the adventitial and periadventitial 
regions of the artery wall [34,35]. Xu et al. suggested that 
the arrangement of the lymphatic vessels within the 
artery wall reflects the importance of this complex net-
work in maintaining the drainage of local inflamma-
tory cells and cytokines from peripheral tissue such as 
the adventitia [36]. In addition of being studied in dog 
epicardial coronary arteries, rabbit carotid and thoracic 
aorta, and rat aortic wall after balloon-induced aortic 
endothelial injury, the presence of lymphatic vessels 
have also been observed in hypercholesterolemic mice. 
In apoE-/- fed on a high-fat western diet, lymphatic 
capillaries have been found in the adventitial layer, 
waving in and out of the adjacent adipose tissue of the 
aorta, and to be quite numerous beneath plaques in the 
aortic sinus [37].
In a clinical setting, Drozdz et al. took interest in the 
presence of lymphatics in the adventitia of the internal 
carotid artery in humans and showed that the number 
of adventitial lymphatics increases with severity of ath-
erosclerosis measured as intimal thickness [38]. Where 
it becomes particularly interesting, is that they stipu-
late that arteries that are covered by a dense network 
of lymphatic vessels seem naturally protected against 
atherosclerosis when compared with those that lack 
such a network [39]. In addition, Kholova et al. have 
published that lymphatic vessels can also be found in 
the intima of advanced lesions [40]. On the other hand, 
other teams observed no [41] or very little [42] lymphatic 
vessels in the wall of normal or atherosclerotic human 
epicardial coronary arteries, despite the accentuated 
presence of VEGF-C [42].
Controversial morphological characterizations 
described above certainly deserve critical consideration. 
For example, what does the presence of lymphatic ves-
sels in the adventitia of the aortic wall really means? 
Are plaque-associated lymphatic vessels friends or foes 
in atherosclerosis? Research groups are actively seeking 
for the answers, especially through altering lymphatic 
function in animal models of atherosclerosis.
Lymphatic function in atherosclerosis
Three decades after Lemole reported observational 
studies considering a connection between intimal 
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edema and lymphatics [33], genetic and surgical inter-
ventions in animal models have emerged, in the faith 
of getting better insights on the role of the lymphatic 
network in atherosclerosis.
Recently, a functional and quantitative study has 
reported the prerequisite role of the lymphatic system 
in the removal of cholesterol from the artery wall, put-
ting front stage the importance of the lymphatic net-
work in mRCT [37]. Using a surgical model of aortic 
transplant from a hypercholesterolemic apolipoprotein 
E-deficient (Apoe-/-) donor to a hypercholesterolemic 
Apoe-/- receiver in which ApoE vector was injected to 
induce cholesterol efflux, it has been shown that the 
pattern of the newly regrown lymphatic vessels post-
transplant is influenced by the blood flow through 
the transplant [37]. The lymphatic vessels thus formed 
appeared to be atheroprotective: in conditions where 
lymphatic vessels had fully grown posttransplant, the 
cholesterol contained in the transplanted artery was 
able to exit the atherosclerotic lesion. By contrast, par-
tial inhibition of lymphatic regrowth using VEGFR-3 
antibody was reflected by retention of cholesterol in the 
artery wall of the transplanted aortic segment [37].
Genetic manipulations in mice have also brought 
new insights on the link between impaired lymphatic 
vessels and atherogenesis. Primary congenital lymph-
edema (Milroy disease) is a rare autosomal dominant 
condition caused by mutations in the vegfr-3 gene [3]. 
Primary human lymphedema is characterized by a 
chronic and disfiguring swelling of the extremities. A 
mouse model to study the physiological regulation of 
lymph flow and to assess the therapeutic potential of 
VEGF-C to stimulate lymphatic revascularization has 
been put forth by Karkkainen et al. [3]. Called ‘Chy 
mice’ because of their apparent development of chy-
lous ascites after birth, this mouse model of lymph-
edema has an inactivating vegfr-3 mutation in their 
germ line, causing a selective incomplete development 
of lymphatic vessels dermally and thus swelling of the 
limbs [2]. Furthermore, despite the complete loss of 
initial lymphatics in the limbs and ears resulting in 
impaired cell trafficking through lymph, the scarce 
lymphatics present in the body trunk reflected a nor-
mal dendritic cell transport [43]. An additional mouse 
model has been reported to inhibit the formation of 
the dermal lymphatic vasculature [44]. Mice express-
ing soluble VEGFR-3 under the keratin-14 (K14) pro-
moter (K14-Vegfr-3-Ig) display a neutralized activity 
of VEGF-C and VEGF-D in the dermal lymphatic 
vasculature when expressed in mouse epidermis. They, 
therefore, also show impairment in transport of solutes 
and dendritic cells from the skin to the corresponding 
draining LNs [44]. Vuorio et al. took advantage of these 
characterized mouse models and analyzed the effects 
of the absence of lymphatics on lipoprotein metabo-
lism and atherosclerosis [45]. Crossing each of these 
two transgenic mouse models baring lymphatic insuf-
ficiency with atherosclerotic mice (Ldlr-/-/Apob100/100), 
the group observed a positive correlation between ath-
eroma formation and the absence of lymphatic vessels. 
They showed that both sVegfr-3×Ldlr-/-/Apob100/100 and 
Chy×Ldlr-/-/Apob100/100 mice have increased cholesterol 
levels leading to accelerated atherogenesis, suggesting 
that lymphatic vessels have an important role in main-
taining proper lipoprotein metabolism and vascular 
homeostasis [45].
Inflammation being a critical part of the athero-
sclerotic process, studies of VEGF-C in inflammatory 
bowel disease (IBD) might be relevant to atheroscle-
rosis. Crohn’s disease and several types of intestinal 
ulcers are diseases associated with an aberrant mucosal 
immune response. Recently, D’Alessio et al. showed 
remarkable results, which demonstrated that adenovi-
ral induction of prolymphangiogenic factor VEGF-C 
provides marked protection against the development 
of acute and chronic colitis in two different animal 
models [46]. They explained the protective function 
of VEGF-C as being meditated by the ‘resolving mac-
rophages,’ as they call them, in a STAT6-dependent 
manner. This VEGF-C/VEGFR-3 pathway that seems 
to regulate macrophage plasticity and activation proves 
hopeful for the correction of defective lymphatic func-
tion especially when it comes to the process of plaque 
formation in atherosclerosis, particularly in mRCT. 
Another group recently published that lymphatic 
impairment worsened the atherosclerosis plaque forma-
tion in atherogenic LDLR-/-/ApoB100/100 mice crossed 
with transgenic mice baring lymphatic localized insuf-
ficiency, without, however, affecting the RCT rate [45]. 
In addition to being a key element in promoting the 
cholesterol efflux from the atherosclerotic lesion, 
the lymphatic network is thought to play a crucial 
role in the transport of immune cells involved in the 
inflammatory response driving plaque progression [47].
Lymph composition in lymphatic function
One of the main role of the lymphatic system is to 
preserve fluid homeostasis within the body [15] by 
absorbing lymph from the peripheral tissue and bring-
ing it back to the bloodstream. Lymph is thus rich in 
lipoproteins such as HDL, immune cells, electrolytes, 
nutrients and antibodies. Lymph composition influ-
ences flow rate, and is believed to modulate lymphatic 
function per se.
Since the early 1970s, it was well known that car-
diac lymph originates from the interstitial fluid, and 
in 1972, Ulall et al. determined the flow character-
istics and composition of normal heart lymph that 
www.future-science.com 10.4155/FSO.15.61 future science group
Lymphatic network in atherosclerosis: the underestimated path    Review
would serve as an essential baseline for future obser-
vations [48]. The average lymph chloride and sodium 
concentrations were higher, whereas the potassium 
concentration was lower, when compared with blood. 
Furthermore, all the protein fractions were present in 
cardiac lymph, but in different concentrations and pro-
portions, as the albumin/globulin ratio was higher in 
cardiac lymph. The cardiac lymph showed a signifi-
cantly higher mean lactate level when compared with 
the coronary sinus blood samples, and the cardiac 
lymph pH was situated at around 8.0 or higher [48]. 
By 1983, Sloop et al. further characterized the chemi-
cal composition and physical appearance of peripheral 
lymph HDL that was markedly different from that of 
plasma HDL, especially in cholesterol-fed dogs [49,50]. 
Lymph HDL had higher cholesterol to protein ratio 
and markedly increased free cholesterol content when 
compared with plasma HDL. The phospholipid con-
tent of lymph HDL was higher than that of plasma 
HDL, while the protein content was lower.
Although peripheral lymph lipoproteins have been 
characterized in animals, there is scarce information 
about their composition, and close to none about their 
ultrastructure, in normal humans. There are however, 
some studies that have started to emerge, analyzing 
human lymph [51]. Several studies have confirmed that 
lymph composition is different than that of plasma 
or serum. Back in 2000, Nanjee et al. elucidated the 
fact that the concentration of small prebeta HDLs 
in human tissue fluids is determined only in part by 
their transfer across lymphatic capillary endothelium 
from plasma. They showed that local production, by 
remodeling of spheroidal HDLs in tissue fluids, is just 
as important [52]. Continuing down this path, in 2001, 
Nanjee et al. made observations regarding the composi-
tion, as well as the ultrastructure of different subclasses 
of normal human peripheral lymph lipoproteins [53]. 
Apolipoprotein B was found almost exclusively in 
low density lipoproteins, and more importantly, total 
cholesterol concentration in lymph HDL was 30% 
greater than could be explained by the transendothelial 
transfer of HDL from plasma, which provided direct 
confirmation that HDL acquires cholesterol in the 
extravascular compartment [53].
We now know that a broad array of cytokines, 
proteins, growth factors are contained within lym-
phatic fluid, which play an important role in metab-
olism, proliferation, as well as an immunoregulatory 
role [54]. When comparing with serum concentra-
tions, Zaleska et al. concluded the existence of a local 
autonomous regulatory humoral mechanism in tissues, 
not reflected in serum, after assessing the fact that 
local cells contribute to lymph concentration by own 
production.
Propelling the lymph down the road: 
the physiology of the contraction
Lymph production has a significant impact on lym-
phatic vessels capacity to actively participate to lymph 
flow [55]. Lymph transport throughout the lymphatic 
network is regulated by different mechanisms that 
are either extrinsic or intrinsic to the lymphatic ves-
sels. The relative importance of intrinsic and extrin-
sic pumping mechanisms varies from a lymphatic bed 
to another. The extrinsic mechanisms include lymph 
generation, arteriolar gradient and surrounding muscle 
contraction (skeletal or smooth muscle). Active trans-
port of lymph is also possible through contraction of 
collecting lymphatic vessels, considered as intrinsic 
lymph transport mechanism. Since changes in pres-
sure and flow are both causes and effects of adaptive 
processes, it becomes crucial to study the adaptation 
of the lymphatic network. Therefore, a recent study 
by Dongaonkar et al. attested the changes in mesen-
teric lymphatic muscle mechanical properties and the 
intracellular Ca2+ in response to sustained mesenteric 
venous hypertension [56]. They showed that following 
3 days of mesenteric venous hypertension, the adap-
tive response of postnodal mesenteric lymphatic vessels 
resulted in weaker pumps with decreased cytosolic Ca2+ 
concentration. So when it comes to the lymphatics role 
in mRCT, it is no surprise that further understanding 
of the physiological characteristics of lymphatic vessel 
pumping and general dynamics is required.
Although LECs lining the lumen of the vessel are 
important modulators of lymphatic contraction, 
lymphatic SMC (LSMC) are described as the active 
components, generating both force and rhythmicity 
responsible to lymph flow. LSMCs wrap lymphangions 
in a disorderly mesh-like structure [57]. Accordingly, 
lymphatic valves function (open–close transitions) is 
passive and responds to differential pressure between 
pre- and post-valve lymphagions [58]. Conversely, 
lymphangion contraction is an active process, requir-
ing the generation of force by the smooth muscle cells. 
Such process mainly depends on myocyte intracellular 
Ca2+ levels. As described in the following section, most 
mechanisms triggering or modulating vessel phasic or 
tonic contraction are influencing LSMCs cytoplasmic 
Ca2+ levels. Increase in cytoplasmic Ca2+ leads to its 
complexing with calmodulin, which activates myosin 
light chain kinase (MLCK). MLCK stimulates gen-
eration of force by the myosin/actin interactions and 
movement. As in blood vessels, Ca2+ dependence of 
the contractile apparatus can also be modulated and 
has a significant impact on myocyte contraction [59,60]. 
Although currently understudied, this regulatory 
pathway is nonetheless quite effective. However, its 
involvement in the regulation of lymphatic vessels 
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active pumping might be more relevant in pathological 
conditions.
Lymph flux upstream will increase intraluminal 
pressure within a lymphangion, producing distension 
of the vessel wall. Such stretch will trigger a myogenic 
response from the LSMCs. The ensuing contractions 
of the smooth muscle cells will then increase intralu-
minal pressure and propel the lymph through the fol-
lowing valve and lymphangion [61]. Although the spe-
cific components integrating vessel wall stretching into 
contraction and myogenic contraction remains to be 
clearly established, membrane potential is depolarized 
in stretched LSMCs [62].
In addition to transluminal pressure, lymphatic con-
traction is sensitive to lymph flow. Every contraction 
stroke is associated with a pulsatile fluid movement, a 
nonlaminar lymph flow due to the presence of valves. 
The subsequent shear stress stimulates endothelial cells, 
which modulate LSMCs contraction [63,64]. However, 
there are several limitations to interpreting the role of 
shear stress in this process. For example, the impact of 
shear stress on endothelial activity is generally studied 
at supraphysiological levels of shear stress. Although 
shear stress in lymphatic vessels is estimated around 0.6 
dyn/cm2, endothelial activation reaches a plateau when 
exposed to shear stress higher than 3 dyn/cm2. These 
experiments are generally carried out in cultured cells, 
where phenotype alteration might result in a significant 
modification of the effect observed. Moreover, loss of 
communication with the underlying smooth muscle 
could also be responsible for changes in sensitivity to 
lymph flow. However, mathematical models strongly 
suggest that differential flow is responsible for higher 
NO concentration near lymphatic valves [65].
Lymphatic contraction is essentially depending 
on intrinsic LSMCs properties. However, the myo-
cytes undergo several regulatory influences, including 
humoral and neural. The most important modulator 
of LSMCs contraction is the endothelium as endothe-
lium strongly regulates lymphatic smooth muscle elec-
trical excitability and contractility. This control occurs 
mainly through the generation and release of nitric 
oxide (NO), although other endothelial derived vasoac-
tive molecules including but not limited to arachidonic 
acid derivatives (e.g., prostacyclin, thromboxane A2) 
and endothelin-1 have also been reported to modu-
late lymphatic contraction dynamics. However, several 
other candidates in endothelial-dependent modulation 
of lymphatic contraction have not been explored yet. 
For example, local ATP release by Pannexin channels 
could activate nearby purinergic receptors. Similarly, 
opening of endothelial K+ channels such as KCa2.3 or 
KCa3.1 channels might lead to ‘K
+ clouds’, activating 
smooth muscle Kir channels and promoting its relax-
ation (or a decrease in phasic contractions) via myocyte 
hyperpolarization. Interestingly, VEGF-C through its 
binding to VEGFR-3 has also been reported to modu-
late lymphatic pumping as positive chronotrope and 
increased lymphagion dilation [66].
Phasic contractions of lymphangions are also sponta-
neous as they can occur in the absence of stimulation. 
Autonomous contraction is triggered by LSMCs action 
potentials (APs). Interestingly, tight electrical coupling 
between LSMCs allows synchronization of myocytes 
electrophysiological state and coordinated contraction 
within individual lymphangions. APs result from the 
summation of spontaneous transient depolarisations 
(STDs) occurring in LSMCs and might lead to myo-
cyte contraction [67]. Myocyte stretching results in an 
increase in STD and AP frequency and the associated 
contraction. STDs originates from a spontaneous IP3 
receptor-dependent Ca2+ release that activates Ca2+-
activated Cl- channels (ClcCa) [62]. Molecular identity 
of ClcCa remains to be established but growing body 
of evidence suggests that vascular ClcCa might be 
encoded by TMEM16A. As of now there is no informa-
tion available on the impact of the loss of TMEM16A 
expression on lymph propelling, but deleterious effects 
on lymphatic function can be hypothesized. Likewise, 
pathological conditions associated with dysfunctional 
lymphatic vessel contraction could involve alteration 
of TMEM16A functional expression. On the other 
hand, Bestrophins can encode Ca2+-activated Cl- chan-
nels and might also represent lymphatic ClCa, stressing 
out the requirement of further investigation. Despite 
its unresolved identity, repolarizing currents by Clca 
will increase open probability of L-type Ca2+ channels, 
increasing Ca2+ influx and leading to contraction. Simi-
larly to blood vessels, the main voltage-dependent Ca2+ 
channel involved appears to be Cav1.2 but a contribu-
tion of T-type Ca2+ channels to lymphatic pacemaking 
capacity have also been reported [68]. Several other ion 
channels recently found to be important in blood ves-
sels (e.g., two-pores K+, KCNQ channels) have not been 
studied in lymphatic vessels. Their potential absence in 
physiological condition does not warrant unequivocal 
exclusion of pathological involvement.
The mechanisms responsible for the spontaneous ER 
Ca2+-store release leading to STDs remain to be estab-
lished. A Ca2+-induced Ca2+ release coupling might 
be involved, where small Ca2+ entry would favor IP3R 
opening and Ca2+ release [69]. Alternatively, endothe-
lial Ca2+ influx pathways in lymphatic vessels are cur-
rently unknown other than the voltage-dependent Ca2+ 
channels. Recent exciting work on local Ca2+ dynam-
ics in blood vasculature brings enthusing hypotheses. 
Indeed, local Ca2+ entry through TRP channels such 
as TRPV4 [70] or TRPA1 [71] could lead to local Ca2+ 
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increase, with little effect on global Ca2+. Moreover, 
Ca2+ microdomains appears to be tightly regulated by 
multiprotein complexes [71,72]. Local Ca2+ entry through 
voltage-dependent Ca2+ channels (like Ca2+ sparklets) 
might also be involved like in blood vessels.
Despite the fact that each lymphangion contraction 
dynamic is independent (they can be autonomous), 
there is strong evidence that interlymphangions electri-
cal communication allows a synchronization of the ves-
sel contraction and improves stroke efficiency [57]. Inter-
cellular communication is relying on expression of gap 
junction channels, complexes of connexins, well char-
acterized in lymphatic and blood vessels [73,74]. Interest-
ingly, electron microscopy studies showed the presence 
of myoendothelial projections (MEPs) through the 
basal lamina [75]. These MEPs are in fact privileged sites 
of communication between endothelium and myocytes, 
where clustering of specialized protein complexes allow 
specific signaling and microdomains. Direct electrical 
coupling does not seem to occur [76] but is not necessary 
to endothelial-smooth muscle communication as dif-
fusible molecules can be involved, as ‘K+ clouds’ or even 
NO production in these juxtaposed structures.
Conclusion & future perspective
Tremendous progresses have been made toward under-
standing the mechanisms bridging lymphatic biology 
to chronic inflammatory disease such as atheroscle-
rosis. Development of genetic mouse models, surgi-
cal methods and functional tools has contributed to 
the exponential advances made in the field in the last 
decades. Notwithstanding of the significant advances, 
it is clear from the research highlighted in this article 
that there is still much to learn about the role of the 
lymphatic network in coronary heart disease. In the 
near future, new therapies targeting the functional 
link between lymphatic dysfunction and atherosclero-
sis are predicted to emerge with continuously promis-
Executive summary
Background
s  Tools to study the venous and arterial circulation have been developed at a greater pace, while exploring the 
lymphatic network had its load of difficulties.
s  Tremendous progress in lymphatic biology has been made since the turn of the present century: new genetic 
mouse models and imaging tools, developed for both animals and humans.
s  This article highlights how progress has contributed to unraveling the role of the lymphatic system in different 
pathophysiologic conditions, such as in atherosclerosis.
Historical perspective
s While practicing vivisection on a dog, Gasparo Aselli and a group of colleagues depicted the ‘vessels 
containing white blood’ described by Hippocrates in 400 BC.
General anatomy & functions of the lymphatic vessels
s  The lymphatic network is an essential component of the immune system, and is required for the maintenance 
of fluid homeostasis within the body.
s  Lymphatic vessels absorb lymph through blind-ended lymphatic capillaries, which then converges into larger 
precollecting and subsequently collecting lymphatic vessels, responsible of maintaining lymph flow through 
contraction of units called lymphangions.
Lymphatic morphology in atherosclerosis
s  Lymphatic vessels are present in the aortic wall, mostly in the adventitia.
Lymphatic function in atherosclerosis
s  Recently, a functional and quantitative study has reported the prerequisite role of the lymphatic system in the 
removal of cholesterol from the artery wall, putting front stage the importance of the lymphatic network in 
mRCT.
Lymph composition in lymphatic function
s  Lymph is rich in lipoproteins such as HDL, immune cells, electrolytes, nutrients and antibodies.
s  Lymph composition influences flow rate and is believed to modulate lymphatic function per se.
Propelling the lymph down the road: the physiology of the contraction
s  Transport throughout the lymphatic network is regulated by different mechanisms that are both intrinsic and 
extrinsic to lymphatic vessels.
s  Lymphangion contraction is an active process, requiring the generation of force by smooth muscle cells and 
modulated by the endothelium.
Conclusion & future perspective
s  Tremendous progresses have been made toward understanding the mechanisms bridging lymphatic biology, 
to chronic inflammatory disease such as atherosclerosis.
s  Translational studies need to further evolve, in order to soon be able to use lymphatic dysfunction as a clinical 
marker essential for cardiovascular diseases prevention.
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ing results, bringing forward novel perspectives for the 
treatment of atherosclerosis.
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